{ "instance": { "f20f2021_purplebiotech.htm": { "axisCustom": 4, "axisStandard": 16, "contextCount": 241, "dts": { "calculationLink": { "local": [ "ppbt-20211231_cal.xml" ] }, "definitionLink": { "local": [ "ppbt-20211231_def.xml" ] }, "inline": { "local": [ "f20f2021_purplebiotech.htm" ] }, "labelLink": { "local": [ "ppbt-20211231_lab.xml" ] }, "presentationLink": { "local": [ "ppbt-20211231_pre.xml" ] }, "schema": { "local": [ "ppbt-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd" ] } }, "elementCount": 578, "entityCount": 1, "hidden": { "http://Purplebiotech.com/20211231": 27, "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 74, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 107 }, "keyCustom": 155, "keyStandard": 294, "memberCustom": 38, "memberStandard": 23, "nsprefix": "ppbt", "nsuri": "http://Purplebiotech.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://Purplebiotech.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Intangible Assets", "role": "http://Purplebiotech.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Cash and Cash Equivalents", "role": "http://Purplebiotech.com/role/CashandCashEquivalents", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Leases", "role": "http://Purplebiotech.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Other Current Assets", "role": "http://Purplebiotech.com/role/OtherCurrentAssets", "shortName": "Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Other Payables", "role": "http://Purplebiotech.com/role/OtherPayables", "shortName": "Other Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Equity", "role": "http://Purplebiotech.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Share-based Payment Arrangements", "role": "http://Purplebiotech.com/role/SharebasedPaymentArrangements", "shortName": "Share-based Payment Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Transactions and Balances with Related Parties", "role": "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties", "shortName": "Transactions and Balances with Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Commitments and Contingent Liabilities", "role": "http://Purplebiotech.com/role/CommitmentsandContingentLiabilities", "shortName": "Commitments and Contingent Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Research and Development Expenses", "role": "http://Purplebiotech.com/role/ResearchandDevelopmentExpenses", "shortName": "Research and Development Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Statements of Financial Position", "role": "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Statements of Financial Position", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "lang": null, "name": "ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Sales, General and Administrative Expenses", "role": "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses", "shortName": "Sales, General and Administrative Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradingIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Finance Expense (Income), Net", "role": "http://Purplebiotech.com/role/FinanceExpenseIncomeNet", "shortName": "Finance Expense (Income), Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradingIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Taxes on Income", "role": "http://Purplebiotech.com/role/TaxesonIncome", "shortName": "Taxes on Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Employee Benefits", "role": "http://Purplebiotech.com/role/EmployeeBenefits", "shortName": "Employee Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Financial Instruments", "role": "http://Purplebiotech.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://Purplebiotech.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Tables)", "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables", "shortName": "Basis of Preparation of the Consolidated Financial Statements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:ScheduleOfDiscontinuedOperationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Discontinued Operation (Tables)", "role": "http://Purplebiotech.com/role/DiscontinuedOperationTables", "shortName": "Discontinued Operation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:ScheduleOfDiscontinuedOperationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Intangible Assets (Tables)", "role": "http://Purplebiotech.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Cash and Cash Equivalents (Tables)", "role": "http://Purplebiotech.com/role/CashandCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Statements of Operations", "role": "http://Purplebiotech.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Leases (Tables)", "role": "http://Purplebiotech.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfDetailedInformationAboutOtherCcrrentAssetsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Other Current Assets (Tables)", "role": "http://Purplebiotech.com/role/OtherCurrentAssetsTables", "shortName": "Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfDetailedInformationAboutOtherCcrrentAssetsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Other Payables (Tables)", "role": "http://Purplebiotech.com/role/OtherPayablesTables", "shortName": "Other Payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Equity (Tables)", "role": "http://Purplebiotech.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Share-based Payment Arrangements (Tables)", "role": "http://Purplebiotech.com/role/SharebasedPaymentArrangementsTables", "shortName": "Share-based Payment Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfPaymentsToKeyManagementExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Transactions and Balances with Related Parties (Tables)", "role": "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables", "shortName": "Transactions and Balances with Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfPaymentsToKeyManagementExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Research and Development Expenses (Tables)", "role": "http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables", "shortName": "Research and Development Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Sales, General and Administrative Expenses (Tables)", "role": "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables", "shortName": "Sales, General and Administrative Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Finance Expense (Income), Net (Tables)", "role": "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables", "shortName": "Finance Expense (Income), Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Employee Benefits (Tables)", "role": "http://Purplebiotech.com/role/EmployeeBenefitsTables", "shortName": "Employee Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c53", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Changes in Equity", "role": "http://Purplebiotech.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c53", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Financial Instruments (Tables)", "role": "http://Purplebiotech.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DescriptionOfWarrantsToPurchaseAmericanDepositoryShares", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - General (Details)", "role": "http://Purplebiotech.com/role/GeneralDetails", "shortName": "General (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DescriptionOfWarrantsToPurchaseAmericanDepositoryShares", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfFunctionalCurrency", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Details)", "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails", "shortName": "Basis of Preparation of the Consolidated Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfFunctionalCurrency", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c72", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfNatureOfObligationContingentLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of assumptions of carrying amounts of assets and liabilities", "role": "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable", "shortName": "Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of assumptions of carrying amounts of assets and liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c72", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfNatureOfObligationContingentLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutExchangeRatesAndLinkageBasesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:AverageForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of changes in exchange rates", "role": "http://Purplebiotech.com/role/ScheduleofchangesinexchangeratesTable", "shortName": "Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of changes in exchange rates", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutExchangeRatesAndLinkageBasesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:AverageForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DescriptionOfLossPerShareADS", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Significant Accounting Policies (Details)", "role": "http://Purplebiotech.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DescriptionOfLossPerShareADS", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ppbt:NumberOfOperatingSegment", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Discontinued Operation (Details)", "role": "http://Purplebiotech.com/role/DiscontinuedOperationDetails", "shortName": "Discontinued Operation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "ppbt:NumberOfOperatingSegment", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfDiscontinuedOperationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c75", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Discontinued Operation (Details) - Schedule of discontinued operation", "role": "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable", "shortName": "Discontinued Operation (Details) - Schedule of discontinued operation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfDiscontinuedOperationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c75", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:AcquisitionOfTyrnovoDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Intangible Assets (Details)", "role": "http://Purplebiotech.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:AcquisitionOfTyrnovoDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets", "role": "http://Purplebiotech.com/role/ScheduleofintangibleassetsTable", "shortName": "Intangible Assets (Details) - Schedule of intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Cash Flows", "role": "http://Purplebiotech.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Intangible Assets (Details) - Schedule of recognized amounts assets acquired and liabilities assumed", "role": "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable", "shortName": "Intangible Assets (Details) - Schedule of recognized amounts assets acquired and liabilities assumed", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents", "role": "http://Purplebiotech.com/role/ScheduleofcashandcashequivalentsTable", "shortName": "Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c94", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:AgreementLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Leases (Details)", "role": "http://Purplebiotech.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c94", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:AgreementLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c95", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Leases (Details) - Schedule of carrying amounts of right-to-use assets", "role": "http://Purplebiotech.com/role/ScheduleofcarryingamountsofrighttouseassetsTable", "shortName": "Leases (Details) - Schedule of carrying amounts of right-to-use assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c98", "decimals": "-3", "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Leases (Details) - Schedule of maturity analysis of the company's lease liabilities", "role": "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable", "shortName": "Leases (Details) - Schedule of maturity analysis of the company's lease liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfRecognizedInProfitOrLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Leases (Details) - Schedule of amounts recognized in profit or loss", "role": "http://Purplebiotech.com/role/ScheduleofamountsrecognizedinprofitorlossTable", "shortName": "Leases (Details) - Schedule of amounts recognized in profit or loss", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfRecognizedInProfitOrLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutOtherCcrrentAssetsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:GovernmentAuthorities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Other Current Assets (Details) - Schedule of other current assets", "role": "http://Purplebiotech.com/role/ScheduleofothercurrentassetsTable", "shortName": "Other Current Assets (Details) - Schedule of other current assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutOtherCcrrentAssetsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:GovernmentAuthorities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Other Payables (Details) - Schedule of other payables", "role": "http://Purplebiotech.com/role/ScheduleofotherpayablesTable", "shortName": "Other Payables (Details) - Schedule of other payables", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:IssuedSecuritiesPublicOfferingDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Equity (Details)", "role": "http://Purplebiotech.com/role/EquityDetails", "shortName": "Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:IssuedSecuritiesPublicOfferingDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c131", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesAuthorised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Equity (Details) - Schedule of changes in share capital during the year", "role": "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable", "shortName": "Equity (Details) - Schedule of changes in share capital during the year", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c131", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesAuthorised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureGeneralTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "005 - Disclosure - General", "role": "http://Purplebiotech.com/role/General", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DisclosureGeneralTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Equity (Details) - Schedule of changes in share capital during the year", "role": "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable0", "shortName": "Equity (Details) - Schedule of changes in share capital during the year", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c61", "decimals": "-3", "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Equity (Details) - Schedule of information relating to subsidiary that has material non-controlling interests", "role": "http://Purplebiotech.com/role/ScheduleofinformationrelatingtosubsidiarythathasmaterialnoncontrollinginterestsTable", "shortName": "Equity (Details) - Schedule of information relating to subsidiary that has material non-controlling interests", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c163", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:StockOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Share-based Payment Arrangements (Details)", "role": "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails", "shortName": "Share-based Payment Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c163", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:StockOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c3", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Share-based Payment Arrangements (Details) - Summary of number and weighted average exercise prices (in USD) of share options", "role": "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable", "shortName": "Share-based Payment Arrangements (Details) - Summary of number and weighted average exercise prices (in USD) of share options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c61", "decimals": "1", "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "ppbt:ShareBasedPaymentArrangementsOutstandingRestrictedStockUnits", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Share-based Payment Arrangements (Details) - Summary of number of RSUs", "role": "http://Purplebiotech.com/role/SummaryofnumberofRSUsTable", "shortName": "Share-based Payment Arrangements (Details) - Summary of number of RSUs", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c42", "decimals": "0", "lang": null, "name": "ppbt:ShareBasedPaymentArrangementsOutstandingRestrictedStockUnits", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c179", "decimals": "3", "first": true, "lang": null, "name": "ppbt:DescriptionOfSharePriceShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Share-based Payment Arrangements (Details) - Summary of options to service providers were measured at the fair value of the service", "role": "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable", "shortName": "Share-based Payment Arrangements (Details) - Summary of options to service providers were measured at the fair value of the service", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c179", "decimals": "3", "first": true, "lang": null, "name": "ppbt:DescriptionOfSharePriceShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutSharebasedExpenseRecognizedExplanatoryTableTextBloc", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:ShareBasedCompensationResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Share-based Payment Arrangements (Details) - Summary of share based expenses recognized", "role": "http://Purplebiotech.com/role/SummaryofsharebasedexpensesrecognizedTable", "shortName": "Share-based Payment Arrangements (Details) - Summary of share based expenses recognized", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutSharebasedExpenseRecognizedExplanatoryTableTextBloc", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:ShareBasedCompensationResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfPaymentsToKeyManagementExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c191", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of recorded expenses to executive officers", "role": "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable", "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of recorded expenses to executive officers", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfPaymentsToKeyManagementExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c191", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DescriptionOfMaximumRoyaltyAmount", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Commitments and Contingent Liabilities (Details)", "role": "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "shortName": "Commitments and Contingent Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:DescriptionOfMaximumRoyaltyAmount", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Research and Development Expenses (Details) - Schedule of research and development expenses", "role": "http://Purplebiotech.com/role/ScheduleofresearchanddevelopmentexpensesTable", "shortName": "Research and Development Expenses (Details) - Schedule of research and development expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Basis of Preparation of the Consolidated Financial Statements", "role": "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements", "shortName": "Basis of Preparation of the Consolidated Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FeeAndCommissionIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Sales, General and Administrative Expenses (Details)", "role": "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesDetails", "shortName": "Sales, General and Administrative Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FeeAndCommissionIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:EmployeesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Sales, General and Administrative Expenses (Details) - Schedule of sales, general and administrative expenses", "role": "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable", "shortName": "Sales, General and Administrative Expenses (Details) - Schedule of sales, general and administrative expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:EmployeesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FeeAndCommissionExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Finance Expense (Income), Net (Details) - Schedule of Finance expenses", "role": "http://Purplebiotech.com/role/ScheduleofFinanceexpensesTable", "shortName": "Finance Expense (Income), Net (Details) - Schedule of Finance expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FeeAndCommissionExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "ifrs-full:ApplicableTaxRate", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Taxes on Income (Details)", "role": "http://Purplebiotech.com/role/TaxesonIncomeDetails", "shortName": "Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ifrs-full:ApplicableTaxRate", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:EmployeeBenefitBonus", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Employee Benefits (Details)", "role": "http://Purplebiotech.com/role/EmployeeBenefitsDetails", "shortName": "Employee Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:EmployeeBenefitBonus", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c207", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Employee Benefits (Details) - Schedule of post-employee benefits", "role": "http://Purplebiotech.com/role/ScheduleofpostemployeebenefitsTable", "shortName": "Employee Benefits (Details) - Schedule of post-employee benefits", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c207", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Employee Benefits (Details) - Schedule of defined contribution plan in respect of its employees", "role": "http://Purplebiotech.com/role/ScheduleofdefinedcontributionplaninrespectofitsemployeesTable", "shortName": "Employee Benefits (Details) - Schedule of defined contribution plan in respect of its employees", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Financial Instruments (Details)", "role": "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "shortName": "Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c2", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c185", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:IncomelossFromChangeInExchangeRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate", "role": "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable", "shortName": "Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c185", "decimals": "-3", "first": true, "lang": null, "name": "ppbt:IncomelossFromChangeInExchangeRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfFinancialInstrumentsMeasuredAtFairValueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c239", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentDerivativeFinancialLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Financial Instruments (Details) - Schedule of financial instruments measured at fair value", "role": "http://Purplebiotech.com/role/ScheduleoffinancialinstrumentsmeasuredatfairvalueTable", "shortName": "Financial Instruments (Details) - Schedule of financial instruments measured at fair value", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfFinancialInstrumentsMeasuredAtFairValueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c239", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentDerivativeFinancialLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Significant Accounting Policies", "role": "http://Purplebiotech.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfFairValueMeasurementAtLevelsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:SignificantUnobservableInputsExpectedTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Financial Instruments (Details) - Schedule of fair value measurement", "role": "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable", "shortName": "Financial Instruments (Details) - Schedule of fair value measurement", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ppbt:ScheduleOfFairValueMeasurementAtLevelsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ppbt:SignificantUnobservableInputsExpectedTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Discontinued Operation", "role": "http://Purplebiotech.com/role/DiscontinuedOperation", "shortName": "Discontinued Operation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f20f2021_purplebiotech.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDiscontinuedOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]", "terseLabel": "Business Contact", "verboseLabel": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelFaxNumber": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Fax Number of contact personnel.", "label": "Contact Personnel Fax Number", "terseLabel": "Contact Personnel Fax Number" } } }, "localname": "ContactPersonnelFaxNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name", "terseLabel": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard", "terseLabel": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement", "terseLabel": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report", "terseLabel": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://Purplebiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r125" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "Lease liability and right-of-use asset (in Dollars)" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": { "auth_ref": [ "r88" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other current assets", "terseLabel": "Changes in trade receivables and other current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationExpense": { "auth_ref": [ "r88" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for depreciation expense", "terseLabel": "Depreciation" } } }, "localname": "AdjustmentsForDepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in employee benefit liabilities", "terseLabel": "Changes in post-employment benefit liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "auth_ref": [ "r86" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in other operating payables", "terseLabel": "Changes in other payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r86" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ppbt_AdjustmentsForChangesInAssetsAndLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "terseLabel": "Changes in accounts payable" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "auth_ref": [ "r88" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments to reconcile profit (loss)", "totalLabel": "Total adjustments" } } }, "localname": "AdjustmentsForReconcileProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r87" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based payments", "verboseLabel": "Total share-based expense recognized" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow", "http://Purplebiotech.com/role/SummaryofsharebasedexpensesrecognizedTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r20", "r55", "r121", "r128", "r129", "r153", "r164", "r166", "r179", "r180", "r181", "r182" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "domainItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r49" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "Tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r17", "r115", "r116", "r117", "r171", "r174" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_AverageForeignExchangeRate": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } }, "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Representative exchange rate (NIS/USD 1)" } } }, "localname": "AverageForeignExchangeRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinexchangeratesTable" ], "xbrltype": "decimalItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r163" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Bear fixed interest, percentage" } } }, "localname": "BorrowingsInterestRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r118", "r119", "r120", "r140", "r163", "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]", "netLabel": "Bottom of Range [member]", "terseLabel": "Bottom of range [Member]", "verboseLabel": "Down Range [Member]" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable", "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable", "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails", "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalReserve": { "auth_ref": [ "r17" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the capital reserves." } }, "en-us": { "role": { "label": "Capital reserve", "terseLabel": "Capital reserve from transactions with related parties" } } }, "localname": "CapitalReserve", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r94" ], "calculation": { "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable": { "order": 1.0, "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r13", "r94", "r113" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at end of the year", "periodStartLabel": "Cash and cash equivalents at the beginning of the year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r80", "r95" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "terseLabel": "Net cash from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities from continuing operation:" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r149" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]" } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities, continuing operations", "totalLabel": "Net cash provided by financing activities from continuing operation" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r80", "r95" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash provided by (used in) investing activities from continuing operation" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investing activities from continuing operation:" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r80", "r95" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Net cash provided by (used in) discontinued operation", "terseLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities from continuing operation:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r149" ], "lang": { "en": { "role": { "documentation": "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities, discontinued operations", "terseLabel": "Net cash (used in) provide by operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperations": { "auth_ref": [ "r88", "r96" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } }, "en-us": { "role": { "label": "Cash flows from (used in) operations", "totalLabel": "Net cash used in operating activities from continuing operation" } } }, "localname": "CashFlowsFromUsedInOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r68" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable", "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r156", "r157", "r159", "r161" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/LeasesDetails", "http://Purplebiotech.com/role/ScheduleofcarryingamountsofrighttouseassetsTable" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r156", "r157", "r159", "r161" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r3", "r35", "r98", "r100", "r105", "r109" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "terseLabel": "Loss for the year" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContinuingAndDiscontinuedOperationsAxis": { "auth_ref": [ "r152" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Continuing and discontinued operations [axis]" } } }, "localname": "ContinuingAndDiscontinuedOperationsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "stringItemType" }, "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": { "auth_ref": [ "r165" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]" } } }, "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable", "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } }, "en-us": { "role": { "label": "Current accrued expenses and other current liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets [Abstract]" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": { "auth_ref": [ "r21" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]" } }, "en-us": { "role": { "label": "Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } }, "en-us": { "role": { "label": "Current derivative financial liabilities", "terseLabel": "Convertible debt instrument (see Note 19B(1))" } } }, "localname": "CurrentDerivativeFinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffinancialinstrumentsmeasuredatfairvalueTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r122" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Current maturity of lease liabilities" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r22", "r105", "r107" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxLiabilities": { "auth_ref": [ "r14", "r18", "r50" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } }, "en-us": { "role": { "label": "Deferred tax liabilities", "terseLabel": "Unrecognized research and development expenses" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation expense", "terseLabel": "Depreciation" } } }, "localname": "DepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedLabel": "Depreciation on right-to-use assets" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcarryingamountsofrighttouseassetsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for derivative financial instruments and hedging. [Refer: Financial instruments, class [member]; Derivatives [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for derivative financial instruments and hedging [text block]", "terseLabel": "Financial instruments" } } }, "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForDiscontinuedOperationsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for discontinued operations. [Refer: Discontinued operations [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for discontinued operations [text block]", "terseLabel": "Discontinued operations" } } }, "localname": "DescriptionOfAccountingPolicyForDiscontinuedOperationsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for earnings per share." } }, "en-us": { "role": { "label": "Description of accounting policy for earnings per share [text block]", "terseLabel": "Loss per share" } } }, "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Employee benefits" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for financial instruments [text block]", "terseLabel": "Financing income and expense" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for foreign currency translation." } }, "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency transactions" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of assets." } }, "en-us": { "role": { "label": "Description of accounting policy for impairment of assets [text block]", "terseLabel": "Impairment" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for income tax." } }, "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Income tax expense" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } }, "en-us": { "role": { "label": "Description of accounting policy for intangible assets and goodwill [text block]", "terseLabel": "Intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue" } } }, "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payment transactions" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAcquisitionOfEntityByMeansOfEquityIssue": { "auth_ref": [ "r93" ], "lang": { "en": { "role": { "documentation": "The description of the non-cash acquisition of an entity by means of an equity issue." } }, "en-us": { "role": { "label": "Description of acquisition of entity by means of equity issue", "terseLabel": "Acquisition of Famewave description" } } }, "localname": "DescriptionOfAcquisitionOfEntityByMeansOfEquityIssue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfFullyAmortisedIntangibleAssets": { "auth_ref": [ "r79" ], "lang": { "en": { "role": { "documentation": "The description of fully amortised intangible assets that are still in use. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description of fully amortised intangible assets", "terseLabel": "Recoverability of intangible assets" } } }, "localname": "DescriptionOfFullyAmortisedIntangibleAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfFunctionalCurrency": { "auth_ref": [ "r59", "r60" ], "lang": { "en": { "role": { "documentation": "The description of the currency of the primary economic environment in which the entity operates." } }, "en-us": { "role": { "label": "Description of functional currency", "terseLabel": "Functional and presentation currency, description" } } }, "localname": "DescriptionOfFunctionalCurrency", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfNatureOfObligationContingentLiabilities": { "auth_ref": [ "r74" ], "lang": { "en": { "role": { "documentation": "The description of the nature of the obligation for contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Description of nature of obligation, contingent liabilities", "terseLabel": "Assessment of probability of contingent liabilities" } } }, "localname": "DescriptionOfNatureOfObligationContingentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r141" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk free rate interest rate (%)" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": { "auth_ref": [ "r72", "r73" ], "lang": { "en": { "role": { "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share from discontinued operations", "terseLabel": "Basic & diluted loss (profit) per ADS \u2013 USD (in Dollars per share)" } } }, "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "perShareItemType" }, "ifrs-full_DirectorsRemunerationExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of remuneration paid or payable to the entity's directors." } }, "en-us": { "role": { "label": "Directors' remuneration expense", "terseLabel": "Board member remuneration and insurance" } } }, "localname": "DirectorsRemunerationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of Preparation of the Consolidated Financial Statements" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/CashandCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r31" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in share capital during the year" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "terseLabel": "Commitments and contingent liabilities" } } }, "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "auth_ref": [ "r77" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of discontinued operations. [Refer: Discontinued operations [member]]" } }, "en-us": { "role": { "label": "Disclosure of discontinued operations [text block]", "terseLabel": "Discontinued operation" } } }, "localname": "DisclosureOfDiscontinuedOperationsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/DiscontinuedOperation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } }, "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Schedule of sensitivity test to possible changes in USD/NIS exchange rate" } } }, "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for employee benefits." } }, "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "Employee benefits" } } }, "localname": "DisclosureOfEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefits" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r168" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial Instruments" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]" } }, "en-us": { "role": { "label": "Disclosure of general and administrative expense [text block]", "terseLabel": "Sales, General and Administrative Expenses" } } }, "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Taxes on Income" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncome" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r142" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "terseLabel": "Summary of options to service providers were measured at the fair value of the service" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r130", "r131" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Leases" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [text block]", "terseLabel": "Schedule of maturity analysis of the company's lease liabilities" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r138" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Summary of number and weighted average exercise prices (in USD) of share options" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "auth_ref": [ "r171" ], "lang": { "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } }, "en-us": { "role": { "label": "Disclosure of operating segments [text block]", "terseLabel": "Schedule of Finance expenses" } } }, "localname": "DisclosureOfOperatingSegmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinanceExpenseIncomeNetTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]" } }, "en-us": { "role": { "label": "Disclosure of other non-current assets [text block]", "terseLabel": "Other Current Assets" } } }, "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/OtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": { "auth_ref": [ "r75" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets." } }, "en-us": { "role": { "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]", "terseLabel": "Provisions" } } }, "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of carrying amounts of right-to-use assets" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Disclosure of research and development expense [text block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ResearchandDevelopmentExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Equity" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Share-based Payment Arrangements" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangements" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Other Payables" } } }, "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/OtherPayables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTradingIncomeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of trading income (expense). [Refer: Trading income (expense)]" } }, "en-us": { "role": { "label": "Disclosure of trading income (expense) [text block]", "terseLabel": "Finance Expense (Income), net" } } }, "localname": "DisclosureOfTradingIncomeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinanceExpenseIncomeNet" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Transactions and Balances with Related Parties" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedParties" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DiscontinuedOperationsMember": { "auth_ref": [ "r152" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of an entity that either has been disposed of or is classified as held for sale, and that: (a) represents a separate major line of business or geographical area of operations; (b) is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or (c) is a subsidiary acquired exclusively with a view to resale. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Discontinued operations [member]", "terseLabel": "Discontinued Operation [Member]" } } }, "localname": "DiscontinuedOperationsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "domainItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r89", "r90" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Effect of translation adjustments on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r68" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r17", "r26", "r97", "r99", "r115", "r116", "r117" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Equity" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r17" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParent": { "auth_ref": [ "r16" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } }, "en-us": { "role": { "label": "Equity attributable to owners of parent", "totalLabel": "Equity attributable to owners of the Company" } } }, "localname": "EquityAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "auth_ref": [ "r141" ], "lang": { "en": { "role": { "documentation": "The exercise price of share options granted." } }, "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Termination exercise price (in Dollars per share)" } } }, "localname": "ExercisePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r141" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected dividend as percentage, share options granted", "terseLabel": "Dividend yield (%)" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Expense from share-based payment transactions", "terseLabel": "Share-based payment arrangements" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets": { "auth_ref": [ "r154" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The fair value of a financial instrument, recognised as an asset, on discontinuation of its measurement at fair value through profit or loss, because a credit derivative is used to manage the credit risk of that financial instrument. [Refer: Credit risk [member]; Derivatives [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Fair value of financial instrument on discontinuation of measurement at fair value through profit or loss because credit derivative is used to manage credit risk, assets", "terseLabel": "Fair value financial instrument" } } }, "localname": "FairValueOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FeeAndCommissionExpense": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } }, "en-us": { "role": { "label": "Fee and commission expense", "terseLabel": "Fees and interest expense" } } }, "localname": "FeeAndCommissionExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FeeAndCommissionIncome": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income relating to fees and commissions." } }, "en-us": { "role": { "label": "Fee and commission income", "terseLabel": "Legal expenses" } } }, "localname": "FeeAndCommissionIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r39" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ppbt_FinanceExpensesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "terseLabel": "Finance expenses" } } }, "localname": "FinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r42" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "ppbt_FinanceExpensesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "negatedLabel": "Finance income" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Gains (losses) on exchange differences on translation of foreign operations, net of tax", "terseLabel": "Loss from exchange rate differences, net" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsOnLitigationSettlements": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gain on settlements of litigation." } }, "en-us": { "role": { "label": "Gains on litigation settlements", "terseLabel": "Gains on litigation settlements" } } }, "localname": "GainsOnLitigationSettlements", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": { "auth_ref": [ "r144", "r145" ], "calculation": { "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Identifiable assets acquired (liabilities assumed)", "totalLabel": "Total net identifiable assets" } } }, "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": { "auth_ref": [ "r144", "r145" ], "calculation": { "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable": { "order": 2.0, "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]" } }, "en-us": { "role": { "label": "Identifiable intangible assets recognised as of acquisition date", "terseLabel": "Intangible assets" } } }, "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeExpensesFromReinsuranceContractsHeldOtherThanFinanceIncomeExpenses": { "auth_ref": [ "r178", "r183" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ppbt_FinanceExpensesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income (expenses) from a group of reinsurance contracts held, other than finance income (expenses). [Refer: Reinsurance contracts held [member]]" } }, "en-us": { "role": { "label": "Income (expenses) from reinsurance contracts held, other than finance income (expenses)", "negatedLabel": "Expenses (income) on account of warrants" } } }, "localname": "IncomeExpensesFromReinsuranceContractsHeldOtherThanFinanceIncomeExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r40", "r47", "r48", "r49", "r69", "r114", "r170" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "terseLabel": "Tax expenses, net" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities": { "auth_ref": [ "r81", "r92" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as investing activities. [Refer: Income taxes paid (refund)]" } }, "en-us": { "role": { "label": "Income taxes paid (refund), classified as investing activities", "negatedLabel": "Net cash from investing activities" } } }, "localname": "IncomeTaxesPaidRefundClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r94" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } }, "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Exercise of warrants" } } }, "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payments" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from transactions with owners." } }, "en-us": { "role": { "label": "Increase (decrease) through transactions with owners, equity", "terseLabel": "Total transactions with owners of the Company" } } }, "localname": "IncreaseDecreaseThroughTransactionsWithOwners", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwill": { "auth_ref": [ "r17" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill", "terseLabel": "Total intangible assets" } } }, "localname": "IntangibleAssetsAndGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r12", "r76" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r124" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "terseLabel": "Interest expenses on lease liability" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofamountsrecognizedinprofitorlossTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } }, "en-us": { "role": { "label": "Interest paid, classified as financing activities", "negatedLabel": "Interest paid" } } }, "localname": "InterestPaidClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": { "auth_ref": [ "r70" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]" } }, "en-us": { "role": { "label": "Investments in subsidiaries, joint ventures and associates reported in separate financial statements", "terseLabel": "Other investment" } } }, "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfConvertibleInstruments": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } }, "en-us": { "role": { "label": "Issue of convertible instruments", "terseLabel": "Convertible note amount" } } }, "localname": "IssueOfConvertibleInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of equity" } } }, "localname": "IssueOfEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r26" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital, no par value" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation", "terseLabel": "Total" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, post-employment benefits", "terseLabel": "Post-employment benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofpostemployeebenefitsTable", "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share based payments" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Short - term employee benefits", "verboseLabel": "Short-term benefits" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofpostemployeebenefitsTable", "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "auth_ref": [ "r8", "r128", "r129", "r164", "r167", "r182" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } }, "en-us": { "role": { "label": "Later than four years and not later than five years [member]", "terseLabel": "One to five years [Member]" } } }, "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r122" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Total" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseReceivablesMember": { "auth_ref": [ "r155", "r158", "r160" ], "lang": { "en": { "role": { "documentation": "This member stands for receivables related to leases." } }, "en-us": { "role": { "label": "Lease receivables [member]", "terseLabel": "Office Lease [Member]", "verboseLabel": "Lease receivables [member]" } } }, "localname": "LeaseReceivablesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails", "http://Purplebiotech.com/role/ScheduleofcarryingamountsofrighttouseassetsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r54", "r116" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level 1 of fair value hierarchy [member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffinancialinstrumentsmeasuredatfairvalueTable" ], "xbrltype": "domainItemType" }, "ifrs-full_Level2OfFairValueHierarchyMember": { "auth_ref": [ "r116" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } }, "en-us": { "role": { "label": "Level 2 of fair value hierarchy [member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "Level2OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffinancialinstrumentsmeasuredatfairvalueTable" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r54", "r116" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffinancialinstrumentsmeasuredatfairvalueTable" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_LongtermDeposits": { "auth_ref": [ "r17" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } }, "en-us": { "role": { "label": "Long-term deposits", "terseLabel": "Long term deposits" } } }, "localname": "LongtermDeposits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r20", "r55", "r121", "r128", "r129", "r153", "r162", "r164", "r179", "r180", "r181", "r182" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "stringItemType" }, "ifrs-full_NetAssetsLiabilities": { "auth_ref": [ "r8", "r101" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } }, "en-us": { "role": { "label": "Assets (liabilities)", "terseLabel": "Net assets" } } }, "localname": "NetAssetsLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofinformationrelatingtosubsidiarythathasmaterialnoncontrollinginterestsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncontrollingInterests": { "auth_ref": [ "r15", "r102", "r104" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Non-controlling interests", "terseLabel": "Non-controlling interests" } } }, "localname": "NoncontrollingInterests", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncontrollingInterestsMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } }, "en-us": { "role": { "label": "Non-controlling interests [member]", "terseLabel": "Non-controlling interests" } } }, "localname": "NoncontrollingInterestsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r21", "r105", "r106" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofinformationrelatingtosubsidiarythathasmaterialnoncontrollinginterestsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r122" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease liability" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r22", "r105", "r108" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non - current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "auth_ref": [ "r25" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } }, "en-us": { "role": { "label": "Non-current provisions for employee benefits", "terseLabel": "Post-employment benefit liabilities" } } }, "localname": "NoncurrentProvisionsForEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r19", "r128", "r129", "r164", "r167", "r182" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Less than one year\t[Member]" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "domainItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r28" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Number of shares, Authorized" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "periodEndLabel": "Issued as at December 31", "periodStartLabel": "Issued as at January 1" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable0" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "auth_ref": [ "r29" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } }, "en-us": { "role": { "label": "Number of shares issued and fully paid", "terseLabel": "Number of shares, Issued and paid-in" } } }, "localname": "NumberOfSharesIssuedAndFullyPaid", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "sharesItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r42" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "totalLabel": "Operating Loss" } } }, "localname": "OperatingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCashAndCashEquivalents": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Other cash and cash equivalents", "terseLabel": "Total cash and cash equivalents" } } }, "localname": "OtherCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentAssets": { "auth_ref": [ "r17" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "verboseLabel": "Total other current assets" } } }, "localname": "OtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ScheduleofothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentPayables": { "auth_ref": [ "r17" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other payables", "verboseLabel": "Other Payables, Total" } } }, "localname": "OtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ScheduleofotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r24" ], "calculation": { "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable": { "order": 3.0, "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinanceCost": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } }, "en-us": { "role": { "label": "Other finance cost", "terseLabel": "Finance expenses, total" } } }, "localname": "OtherFinanceCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherPayables": { "auth_ref": [ "r17" ], "calculation": { "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable": { "order": 5.0, "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other payables", "negatedLabel": "Other payables" } } }, "localname": "OtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReservesMember": { "auth_ref": [ "r6", "r32" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves [member]", "terseLabel": "Equity attributable to owners of parent" } } }, "localname": "OtherReservesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "terseLabel": "Public offering issued value (in Dollars per share)" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liability" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PercentageOfEntitysRevenue": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The percentage of the entity's revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Percentage of entity's revenue", "terseLabel": "Annual interest rate of revenues" } } }, "localname": "PercentageOfEntitysRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } }, "en-us": { "role": { "label": "Post-employment benefit expense, defined contribution plans", "terseLabel": "Amount recognized as expense in respect of defined contribution plan" } } }, "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdefinedcontributionplaninrespectofitsemployeesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r84" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Proceeds from issuance of ADSs" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Placement agent fees and other offering related expenses" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to [abstract]", "terseLabel": "Loss attributable to:" } } }, "localname": "ProfitLossAttributableToAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "auth_ref": [ "r36", "r103" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ppbt_ProfitLossAttributableToOwnersAndIncludingNonControllingInterests", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to non-controlling interests", "terseLabel": "Non-controlling interests" } } }, "localname": "ProfitLossAttributableToNoncontrollingInterests", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r37" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ppbt_ProfitLossAttributableToOwnersAndIncludingNonControllingInterests", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to owners of parent", "terseLabel": "Owners of the Company" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromContinuingOperations": { "auth_ref": [ "r34", "r111", "r171", "r173" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from continuing operations", "negatedTotalLabel": "Loss for the year from continuing operations", "terseLabel": "From continuing operations" } } }, "localname": "ProfitLossFromContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement", "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests": { "auth_ref": [ "r150", "r151" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to non-controlling interests. [Refer: Profit (loss) from continuing operations; Non-controlling interests]" } }, "en-us": { "role": { "label": "Profit (loss) from continuing operations attributable to non-controlling interests", "terseLabel": "Loss for the year" } } }, "localname": "ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofinformationrelatingtosubsidiarythathasmaterialnoncontrollinginterestsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromDiscontinuedOperations": { "auth_ref": [ "r41", "r44", "r112", "r146" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from discontinued operations", "negatedLabel": "Loss (profit) from discontinued operation", "terseLabel": "Loss (profit) for the year", "verboseLabel": "From discontinued operation" } } }, "localname": "ProfitLossFromDiscontinuedOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement", "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r11", "r53" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "terseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfInvestmentProperty": { "auth_ref": [ "r83" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of investment property. [Refer: Investment property]" } }, "en-us": { "role": { "label": "Purchase of investment property", "negatedLabel": "Investment in financial assets and loan granted (See Note 5B)" } } }, "localname": "PurchaseOfInvestmentProperty", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Acquisition of fixed assets" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r118", "r119", "r120", "r140", "r163", "r181" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable", "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable", "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails", "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r118", "r119", "r120", "r140", "r163", "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable", "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable", "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails", "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "domainItemType" }, "ifrs-full_RentalExpense": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense recognised on rental activities." } }, "en-us": { "role": { "label": "Rental expense", "terseLabel": "Maintenance expenses" } } }, "localname": "RentalExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r78" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfSharebasedPayments": { "auth_ref": [ "r26" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity resulting from share-based payments." } }, "en-us": { "role": { "label": "Reserve of share-based payments", "terseLabel": "Capital reserve for share-based payments" } } }, "localname": "ReserveOfSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } }, "en-us": { "role": { "label": "Reserve of share-based payments [member]", "terseLabel": "Capital reserve for share-based payments" } } }, "localname": "ReserveOfSharebasedPaymentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r26", "r46" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated loss" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Accumulated loss" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r38", "r105", "r110", "r147", "r169", "r172", "r175", "r176", "r177" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenue" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r126" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning", "terseLabel": "Right to use assets" } } }, "localname": "RightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/ScheduleofcarryingamountsofrighttouseassetsTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to selling, general and administrative activities of the entity." } }, "en-us": { "role": { "label": "Selling, general and administrative expense", "terseLabel": "Sales, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SeparateManagementEntitiesAxis": { "auth_ref": [ "r67" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Separate management entities [axis]" } } }, "localname": "SeparateManagementEntitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofpostemployeebenefitsTable", "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "stringItemType" }, "ifrs-full_SeparateMember": { "auth_ref": [ "r71" ], "lang": { "en": { "role": { "documentation": "This member stands for separate financial statements. Separate financial statements are those presented by an entity in which the entity could elect, subject to the requirements in IAS 27, to account for its investments in subsidiaries, joint ventures and associates either at cost, in accordance with IFRS 9, or using the equity method as described in IAS 28." } }, "en-us": { "role": { "label": "Separate [member]", "terseLabel": "Separate management entities [member]" } } }, "localname": "SeparateMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofpostemployeebenefitsTable" ], "xbrltype": "domainItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r26" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium", "terseLabel": "Share premium" } } }, "localname": "SharePremium", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet", "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium [member]", "terseLabel": "Share premium" } } }, "localname": "SharePremiumMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Cash and cash equivalents and short-term and long-terms deposits" } } }, "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "auth_ref": [ "r17" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, not classified as cash equivalents", "terseLabel": "Short term deposits" } } }, "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxExpenseRelatingToProfitLossFromOrdinaryActivitiesOfDiscontinuedOperations": { "auth_ref": [ "r51", "r148" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The tax expense (income) relating to the profit (loss) arising from ordinary activities of discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Tax expense (income) relating to profit (loss) from ordinary activities of discontinued operations", "terseLabel": "Expenses" } } }, "localname": "TaxExpenseRelatingToProfitLossFromOrdinaryActivitiesOfDiscontinuedOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r118", "r119", "r120", "r140", "r163", "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "netLabel": "Top of Range [member]", "terseLabel": "Top of range [Member]", "verboseLabel": "Up Range [Member]" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails", "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable", "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable", "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails", "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]" } }, "en-us": { "role": { "label": "Current payables to related parties", "terseLabel": "Due to related parties - payroll related" } } }, "localname": "TradeAndOtherCurrentPayablesToRelatedParties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r23", "r27" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Accounts payable" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "auth_ref": [ "r27" ], "calculation": { "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable": { "order": 4.0, "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } }, "en-us": { "role": { "label": "Trade payables", "negatedLabel": "Trade payables" } } }, "localname": "TradeAndOtherPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecognizedamountsassetsacquiredandliabilitiesassumedTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeReceivables": { "auth_ref": [ "r24" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } }, "en-us": { "role": { "label": "Trade receivables", "terseLabel": "Trade receivables" } } }, "localname": "TradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TravelExpense": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from travel." } }, "en-us": { "role": { "label": "Travel expense", "terseLabel": "Travel and car expenses" } } }, "localname": "TravelExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfInstrumentMember": { "auth_ref": [ "r165" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used." } }, "en-us": { "role": { "label": "Types of instrument [member]" } } }, "localname": "TypesOfInstrumentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "domainItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "terseLabel": "Salaries, wages and related expenses" } } }, "localname": "WagesAndSalaries", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "auth_ref": [ "r137" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement", "terseLabel": "Exercisable on December 31" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r135" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement", "terseLabel": "Expired and forfeited during the year" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r134" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "terseLabel": "Granted during the year" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r133", "r136" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding on December 31", "periodStartLabel": "Outstanding on January 1" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r140" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Weighted average contractual life" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Average price (in Dollars per share)" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "ppbt_ADSAndWarrantsIssuedInConnectionWithThePurchaseOfASubsidiaryseeNote5B": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "ADS and warrants issued in connection with the purchase of a subsidiary.", "label": "ADSAndWarrantsIssuedInConnectionWithThePurchaseOfASubsidiaryseeNote5B", "terseLabel": "ADS and warrants issued in connection with the purchase of a subsidiary (see Note 5B)" } } }, "localname": "ADSAndWarrantsIssuedInConnectionWithThePurchaseOfASubsidiaryseeNote5B", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ppbt_AccountPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AccountPayablesMember", "terseLabel": "Accounts payable [Member]" } } }, "localname": "AccountPayablesMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "domainItemType" }, "ppbt_AcquisitionOfTyrnovoDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition of Tyrnovo description.", "label": "AcquisitionOfTyrnovoDescription", "terseLabel": "Acquisition of tyrnovo, description" } } }, "localname": "AcquisitionOfTyrnovoDescription", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ppbt_AdditionalAcquisitionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional acquisition percentage.", "label": "AdditionalAcquisitionPercentage", "terseLabel": "Additional acquisition percentage" } } }, "localname": "AdditionalAcquisitionPercentage", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "ppbt_AdditionalExercisablePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional exercisable period.", "label": "AdditionalExercisablePeriod", "terseLabel": "Additional exercisable period" } } }, "localname": "AdditionalExercisablePeriod", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "durationItemType" }, "ppbt_AdditionalFairValueOfOptionsAndGrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional fair value of options and grants.", "label": "AdditionalFairValueOfOptionsAndGrants", "terseLabel": "Additional fair value of options and grants" } } }, "localname": "AdditionalFairValueOfOptionsAndGrants", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_AdditionalOfApproximatelyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional of approximately percentage.", "label": "AdditionalOfApproximatelyPercentage", "terseLabel": "Additional of approximately percentage" } } }, "localname": "AdditionalOfApproximatelyPercentage", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "ppbt_AdditionalOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional of ordinary shares.", "label": "AdditionalOfOrdinaryShares", "terseLabel": "Additional of ordinary shares (in Shares)" } } }, "localname": "AdditionalOfOrdinaryShares", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "sharesItemType" }, "ppbt_AdditionalStockOptionExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional stock option exercise price.", "label": "AdditionalStockOptionExercisePrice", "terseLabel": "Additional stock option exercise price (in Dollars per share)" } } }, "localname": "AdditionalStockOptionExercisePrice", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "perShareItemType" }, "ppbt_AdditionalStockOptionGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional stock option granted.", "label": "AdditionalStockOptionGranted", "terseLabel": "Additional stock option granted" } } }, "localname": "AdditionalStockOptionGranted", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_AdditionalVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional vesting period.", "label": "AdditionalVestingPeriod", "terseLabel": "Additional vesting period" } } }, "localname": "AdditionalVestingPeriod", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "durationItemType" }, "ppbt_AdjustmentsForChangesInAssetsAndLiabilities": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for changes in assets and liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "AdjustmentsForChangesInAssetsAndLiabilities", "totalLabel": "Changes in assets and liabilities, total" } } }, "localname": "AdjustmentsForChangesInAssetsAndLiabilities", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_AdsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AdsMember", "terseLabel": "Ads [Member]" } } }, "localname": "AdsMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "ppbt_AggregateConsiderationReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of receive aggregate consideration.", "label": "AggregateConsiderationReceived", "terseLabel": "Aggregate consideration received" } } }, "localname": "AggregateConsiderationReceived", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_AggregateOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "AggregateOfferingPrice", "terseLabel": "Aggregate offering price" } } }, "localname": "AggregateOfferingPrice", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_AgreementLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement Lease Term.", "label": "AgreementLeaseTerm", "terseLabel": "Agreement lease term" } } }, "localname": "AgreementLeaseTerm", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "ppbt_AmericanDepostioryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American depostiory shares.", "label": "AmericanDepostioryShares", "terseLabel": "American depostiory shares (in Shares)" } } }, "localname": "AmericanDepostioryShares", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "sharesItemType" }, "ppbt_BasicAndDilutedEarningsLossesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]", "label": "BasicAndDilutedEarningsLossesPerShare", "terseLabel": "Basic & diluted loss per ADS - USD (in Dollars per share)" } } }, "localname": "BasicAndDilutedEarningsLossesPerShare", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "ppbt_BasicAndDilutedLoss": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.", "label": "BasicAndDilutedLoss", "terseLabel": "Number of ADSs used in calculating basic & diluted loss per ADS (in Shares)" } } }, "localname": "BasicAndDilutedLoss", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "ppbt_BasicDilutedLossprofitDiscontinuedOperation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BasicDilutedLossprofitDiscontinuedOperation", "terseLabel": "Basic & diluted loss (profit) per ADS \u2013 USD (in Dollars per share)" } } }, "localname": "BasicDilutedLossprofitDiscontinuedOperation", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsScheduleofassumptionsofcarryingamountsofassetsandliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of assumptions of carrying amounts of assets and liabilities [Line Items]" } } }, "localname": "BasisofPreparationoftheConsolidatedFinancialStatementsDetailsScheduleofassumptionsofcarryingamountsofassetsandliabilitiesLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "ppbt_BasisofPreparationoftheConsolidatedFinancialStatementsDetailsScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of assumptions of carrying amounts of assets and liabilities [Table]" } } }, "localname": "BasisofPreparationoftheConsolidatedFinancialStatementsDetailsScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "ppbt_BoardMemberSharebasedPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Board member share-based payments.", "label": "BoardMemberSharebasedPayments", "terseLabel": "Board member share-based payments" } } }, "localname": "BoardMemberSharebasedPayments", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BoardOfDirectorsMember", "terseLabel": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterest": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Capital reserve from transactions with non- controlling interest.", "label": "CapitalReserveFromTransactionsWithNon-ControllingInterest", "terseLabel": "Capital reserve from transactions with non- controlling interest" } } }, "localname": "CapitalReserveFromTransactionsWithNon-ControllingInterest", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ppbt_CapitalReserveFromTransactionsWithNon-ControllingInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital reserve from transactions with Non-controlling interest.", "label": "CapitalReserveFromTransactionsWithNon-ControllingInterestMember", "terseLabel": "Capital reserve from transactions with Non-controlling interest" } } }, "localname": "CapitalReserveFromTransactionsWithNon-ControllingInterestMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ppbt_CapitalReserveFromTransactionsWithRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CapitalReserveFromTransactionsWithRelatedPartiesMember", "terseLabel": "Capital reserve from transactions with related parties" } } }, "localname": "CapitalReserveFromTransactionsWithRelatedPartiesMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ppbt_CarryForwardLossesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carry forward losses description.", "label": "CarryForwardLossesDescription", "terseLabel": "Carry forward losses description" } } }, "localname": "CarryForwardLossesDescription", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "ppbt_CashAndCashEquivalentsAndDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashAndCashEquivalentsAndDepositsMember", "terseLabel": "Cash and cash equivalents and deposits [Member]" } } }, "localname": "CashAndCashEquivalentsAndDepositsMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "domainItemType" }, "ppbt_CashAssumedAsPartOfAcquisitionOfFamewave": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of interests in associates. [Refer: Associates [member]]", "label": "CashAssumedAsPartOfAcquisitionOfFamewave", "negatedLabel": "Cash assumed as part of acquisition of FameWave (See Note 5B)" } } }, "localname": "CashAssumedAsPartOfAcquisitionOfFamewave", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_CashFlowsFromDiscontinuedOperation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash flows from discontinued operation.", "label": "CashFlowsFromDiscontinuedOperation", "terseLabel": "Total" } } }, "localname": "CashFlowsFromDiscontinuedOperation", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "monetaryItemType" }, "ppbt_CashFlowsFromDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashFlowsFromDiscontinuedOperationAbstract", "terseLabel": "Cash flows from discontinued operation" } } }, "localname": "CashFlowsFromDiscontinuedOperationAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "stringItemType" }, "ppbt_CashFlowsInRespectOfDiscontinuedOperationAsFollowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashFlowsInRespectOfDiscontinuedOperationAsFollowsAbstract", "terseLabel": "Cash flows in respect of discontinued operation as follows:" } } }, "localname": "CashFlowsInRespectOfDiscontinuedOperationAsFollowsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ppbt_CashandCashEquivalentsDetailsScheduleofcashandcashequivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents [Line Items]" } } }, "localname": "CashandCashEquivalentsDetailsScheduleofcashandcashequivalentsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "stringItemType" }, "ppbt_CashandCashEquivalentsDetailsScheduleofcashandcashequivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents [Table]" } } }, "localname": "CashandCashEquivalentsDetailsScheduleofcashandcashequivalentsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "stringItemType" }, "ppbt_ChairmanOfBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ChairmanOfBoardMember", "terseLabel": "Chairman Of Board [Member]" } } }, "localname": "ChairmanOfBoardMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "ppbt_ChangeDuringYeartoRightofuseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ChangeDuringYeartoRightofuseAssets", "terseLabel": "Change during the year" } } }, "localname": "ChangeDuringYeartoRightofuseAssets", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcarryingamountsofrighttouseassetsTable" ], "xbrltype": "monetaryItemType" }, "ppbt_ChangesInAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ChangesInAssetsAndLiabilitiesAbstract", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "ChangesInAssetsAndLiabilitiesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ppbt_ChangesInExchangeRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of changes in exchages rates.", "label": "ChangesInExchangeRates", "terseLabel": "Changes in exchange rates for the Year ended" } } }, "localname": "ChangesInExchangeRates", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinexchangeratesTable" ], "xbrltype": "percentItemType" }, "ppbt_ChangesInExchangeRatesForTheYearEndedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ChangesInExchangeRatesForTheYearEndedAbstract", "terseLabel": "Changes in exchange rates for the year ended:" } } }, "localname": "ChangesInExchangeRatesForTheYearEndedAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinexchangeratesTable" ], "xbrltype": "stringItemType" }, "ppbt_ClassEPreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ClassEPreferredSharesMember", "terseLabel": "Class E Preferred Shares [Member]" } } }, "localname": "ClassEPreferredSharesMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "domainItemType" }, "ppbt_ClassOfWarrantsOrRightTitleOfSecurityWarrantsOrRightsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item provides the title of issue of securities called for by warrants or rights outstanding.", "label": "ClassOfWarrantsOrRightTitleOfSecurityWarrantsOrRightsOutstanding", "terseLabel": "Description of warrants rights" } } }, "localname": "ClassOfWarrantsOrRightTitleOfSecurityWarrantsOrRightsOutstanding", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ppbt_ClassesOfPreferredSharesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ClassesOfPreferredSharesAxis", "terseLabel": "Classes Of Preferred Shares [Axis]" } } }, "localname": "ClassesOfPreferredSharesAxis", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "stringItemType" }, "ppbt_CommitmentsandContingentLiabilitiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingent Liabilities (Details) [Line Items]" } } }, "localname": "CommitmentsandContingentLiabilitiesDetailsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ppbt_CommitmentsandContingentLiabilitiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingent Liabilities (Details) [Table]" } } }, "localname": "CommitmentsandContingentLiabilitiesDetailsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ppbt_ConsolidatedStatementsOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Changes in Equity [Abstract]" } } }, "localname": "ConsolidatedStatementsOfChangesInEquityAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ContinuingOperationsAbstract", "terseLabel": "Continuing operations" } } }, "localname": "ContinuingOperationsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "ppbt_ConvertibleWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible warrants.", "label": "ConvertibleWarrants", "terseLabel": "Convertible warrants (in Shares)" } } }, "localname": "ConvertibleWarrants", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "sharesItemType" }, "ppbt_CurrentAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of Corrent assets.", "label": "CurrentAsset", "terseLabel": "Current assets" } } }, "localname": "CurrentAsset", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofinformationrelatingtosubsidiarythathasmaterialnoncontrollinginterestsTable" ], "xbrltype": "monetaryItemType" }, "ppbt_CurrentLiabiliti": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CurrentLiabiliti", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabiliti", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofinformationrelatingtosubsidiarythathasmaterialnoncontrollinginterestsTable" ], "xbrltype": "monetaryItemType" }, "ppbt_CurrentTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CurrentTerms", "terseLabel": "Percentage of current terms" } } }, "localname": "CurrentTerms", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "ppbt_Currentmaturitiesofleaseliability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Currentmaturitiesofleaseliability", "terseLabel": "Current maturities of lease liability" } } }, "localname": "Currentmaturitiesofleaseliability", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_DecreaseincreaseInShortandLongTermDeposits": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease increase in Shortand Long Term Deposits.", "label": "DecreaseincreaseInShortandLongTermDeposits", "terseLabel": "Decrease (increase) in short and long term deposits" } } }, "localname": "DecreaseincreaseInShortandLongTermDeposits", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_DepreciationRightofuseAssetsUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DepreciationRightofuseAssetsUsefulLife", "terseLabel": "Lease term" } } }, "localname": "DepreciationRightofuseAssetsUsefulLife", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "ppbt_DerivativeInstrument": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative instrument.", "label": "DerivativeInstrument", "terseLabel": "Derivative instrument" } } }, "localname": "DerivativeInstrument", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for basis of consolidation.", "label": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock", "terseLabel": "Basis of consolidation" } } }, "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "ppbt_DescriptionOfEnforcementArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of Enforcement Arrangement.", "label": "DescriptionOfEnforcementArrangement", "terseLabel": "Description of enforcement arrangement" } } }, "localname": "DescriptionOfEnforcementArrangement", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ppbt_DescriptionOfExpectedTermShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected term of share options granted.", "label": "DescriptionOfExpectedTermShareOptionsGranted", "terseLabel": "Expected duration (years)" } } }, "localname": "DescriptionOfExpectedTermShareOptionsGranted", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "durationItemType" }, "ppbt_DescriptionOfLicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of license agreement.", "label": "DescriptionOfLicenseAgreement", "terseLabel": "Description of license agreement" } } }, "localname": "DescriptionOfLicenseAgreement", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ppbt_DescriptionOfLossPerShareADS": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of loss per share ADS shares.", "label": "DescriptionOfLossPerShareADS", "terseLabel": "Description of Loss Per Share" } } }, "localname": "DescriptionOfLossPerShareADS", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "ppbt_DescriptionOfMaximumRoyaltyAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of maximum royalty amount.", "label": "DescriptionOfMaximumRoyaltyAmount", "terseLabel": "Description of maximum royalty amount" } } }, "localname": "DescriptionOfMaximumRoyaltyAmount", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ppbt_DescriptionOfMotionTotalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of motion total amount.", "label": "DescriptionOfMotionTotalAmount", "terseLabel": "Description of motion total amount" } } }, "localname": "DescriptionOfMotionTotalAmount", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ppbt_DescriptionOfOptionPriceShareOptionsGrantedre": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The option price of share options granted.", "label": "DescriptionOfOptionPriceShareOptionsGrantedre", "terseLabel": "Option price - USD (in Dollars per share)" } } }, "localname": "DescriptionOfOptionPriceShareOptionsGrantedre", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "perShareItemType" }, "ppbt_DescriptionOfPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of public offering.", "label": "DescriptionOfPublicOffering", "terseLabel": "Description of public offering" } } }, "localname": "DescriptionOfPublicOffering", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ppbt_DescriptionOfSharePriceShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The share price of share options granted.", "label": "DescriptionOfSharePriceShareOptionsGranted", "terseLabel": "Share Price - USD (in Dollars per share)" } } }, "localname": "DescriptionOfSharePriceShareOptionsGranted", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "perShareItemType" }, "ppbt_DescriptionOfWarrantsToPurchaseAmericanDepositoryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of warrants to purchase american depository shares.", "label": "DescriptionOfWarrantsToPurchaseAmericanDepositoryShares", "terseLabel": "Description of warrants to purchase ADS" } } }, "localname": "DescriptionOfWarrantsToPurchaseAmericanDepositoryShares", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "xbrltype": "stringItemType" }, "ppbt_DisclosureGeneralAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure General [Abstract]" } } }, "localname": "DisclosureGeneralAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureGeneralTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisclosureGeneralTextBlock", "terseLabel": "General" } } }, "localname": "DisclosureGeneralTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/General" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfBasisOfPreparationOfFinancialStatementsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block] [Abstract]" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfCashAndCashEquivalentsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block] [Abstract]" } } }, "localname": "DisclosureOfCashAndCashEquivalentsTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block] [Abstract]" } } }, "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about cash and cash equivalents.", "label": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "terseLabel": "Schedule of cash and cash equivalents" } } }, "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CashandCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Changes In Share Capital Explanatory Table Text Block.", "label": "DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock", "terseLabel": "Schedule of changes in share capital during the year" } } }, "localname": "DisclosureOfDetailedInformationAboutChangesInShareCapitalExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about defined contribution plan.", "label": "DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock", "terseLabel": "Schedule of defined contribution plan in respect of its employees" } } }, "localname": "DisclosureOfDetailedInformationAboutDefinedContributionPlanExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about employee benefits.", "label": "DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "terseLabel": "Schedule of post-employee benefits" } } }, "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutExchangeRatesAndLinkageBasesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about exchange rates and linkage bases.", "label": "DisclosureOfDetailedInformationAboutExchangeRatesAndLinkageBasesExplanatoryTableTextBlock", "terseLabel": "Schedule of changes in exchange rates" } } }, "localname": "DisclosureOfDetailedInformationAboutExchangeRatesAndLinkageBasesExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutIntangibleAssetsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block] [Abstract]" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock.", "label": "DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock", "terseLabel": "Schedule of information relating to subsidiary that has material non-controlling interests" } } }, "localname": "DisclosureOfDetailedInformationAboutNoncontrollingInterestsTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutOtherCcrrentAssetsExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about other Ccrrent assets explanatory.", "label": "DisclosureOfDetailedInformationAboutOtherCcrrentAssetsExplanatoryTableTextBlock", "terseLabel": "Schedule of other current assets" } } }, "localname": "DisclosureOfDetailedInformationAboutOtherCcrrentAssetsExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/OtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about restricted stock unit.", "label": "DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock", "terseLabel": "Summary of number of RSUs" } } }, "localname": "DisclosureOfDetailedInformationAboutRestrictedStockUnitTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutSharebasedExpenseRecognizedExplanatoryTableTextBloc": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about share-based expense recognized.", "label": "DisclosureOfDetailedInformationAboutSharebasedExpenseRecognizedExplanatoryTableTextBloc", "terseLabel": "Summary of share based expenses recognized" } } }, "localname": "DisclosureOfDetailedInformationAboutSharebasedExpenseRecognizedExplanatoryTableTextBloc", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about of trade and other payables.", "label": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "terseLabel": "Schedule of other payables" } } }, "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/OtherPayablesTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfDiscontinuedOperationsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of discontinued operations [text block] [Abstract]" } } }, "localname": "DisclosureOfDiscontinuedOperationsTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfEmployeeBenefitsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [text block] [Abstract]" } } }, "localname": "DisclosureOfEmployeeBenefitsTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfFinancialInstrumentsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of financial instruments [text block] [Abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales, General and Administrative Expenses [Abstract]" } } }, "localname": "DisclosureOfGeneralAndAdministrativeExpenseTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfIncomeTaxTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of income tax [text block] [Abstract]" } } }, "localname": "DisclosureOfIncomeTaxTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfPaymentsToKeyManagementExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of payments to key management.", "label": "DisclosureOfPaymentsToKeyManagementExplanatoryTableTextBlock", "terseLabel": "Schedule of recorded expenses to executive officers" } } }, "localname": "DisclosureOfPaymentsToKeyManagementExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/TransactionsandBalanceswithRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfResearchAndDevelopmentExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "terseLabel": "Schedule of research and development expenses" } } }, "localname": "DisclosureOfResearchAndDevelopmentExpensesTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ResearchandDevelopmentExpensesTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block] [Abstract]" } } }, "localname": "DisclosureOfShareBasedPaymentArrangementsTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfShareCapitalReservesAndOtherEquityInterestTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block] [Abstract]" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfSignificantAccountingPoliciesTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block] [Abstract]" } } }, "localname": "DisclosureOfSignificantAccountingPoliciesTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfTradeAndOtherPayablesTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block] [Abstract]" } } }, "localname": "DisclosureOfTradeAndOtherPayablesTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfTradingIncomeExpenseTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of trading income (expense) [text block] [Abstract]" } } }, "localname": "DisclosureOfTradingIncomeExpenseTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosureOfTransactionsBetweenRelatedPartiesTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block] [Abstract]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTextBlockAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosures Of DetailedInformationAboutGeneralAndAdministrativeExpenses Explanatory [Table Text Block]", "label": "DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "terseLabel": "Schedule of sales, general and administrative expenses" } } }, "localname": "DisclosuresOfDetailedInformationAboutGeneralAndAdministrativeExpensesExplanatoryTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SalesGeneralandAdministrativeExpensesTables" ], "xbrltype": "textBlockItemType" }, "ppbt_DiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DiscontinuedOperationAbstract", "terseLabel": "Discontinued operation" } } }, "localname": "DiscontinuedOperationAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "ppbt_DiscontinuedOperationDetailsScheduleofdiscontinuedoperationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operation (Details) - Schedule of discontinued operation [Line Items]" } } }, "localname": "DiscontinuedOperationDetailsScheduleofdiscontinuedoperationLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "stringItemType" }, "ppbt_DiscontinuedOperationDetailsScheduleofdiscontinuedoperationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operation (Details) - Schedule of discontinued operation [Table]" } } }, "localname": "DiscontinuedOperationDetailsScheduleofdiscontinuedoperationTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "stringItemType" }, "ppbt_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_DownRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DownRangeOneMember", "terseLabel": "Down Range One [Member]" } } }, "localname": "DownRangeOneMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "domainItemType" }, "ppbt_EmployeeBenefitBonus": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employee benefit bonus.", "label": "EmployeeBenefitBonus", "terseLabel": "Bonuses expenses" } } }, "localname": "EmployeeBenefitBonus", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_EmployeeBenefitsDetailsScheduleofpostemployeebenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits (Details) - Schedule of post-employee benefits [Line Items]" } } }, "localname": "EmployeeBenefitsDetailsScheduleofpostemployeebenefitsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofpostemployeebenefitsTable" ], "xbrltype": "stringItemType" }, "ppbt_EmployeeBenefitsDetailsScheduleofpostemployeebenefitsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits (Details) - Schedule of post-employee benefits [Table]" } } }, "localname": "EmployeeBenefitsDetailsScheduleofpostemployeebenefitsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofpostemployeebenefitsTable" ], "xbrltype": "stringItemType" }, "ppbt_EmployeeBenefitsLiabilityDueGrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employee benefits liability due grants.", "label": "EmployeeBenefitsLiabilityDueGrants", "terseLabel": "Employee benefits liability due grants" } } }, "localname": "EmployeeBenefitsLiabilityDueGrants", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_EmployeesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of employee and officer compensation.", "label": "EmployeesAndOfficersCompensation", "terseLabel": "Employees and officer\u2019s compensation" } } }, "localname": "EmployeesAndOfficersCompensation", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_EquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) [Line Items]" } } }, "localname": "EquityDetailsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ppbt_EquityDetailsScheduleofchangesinsharecapitalduringtheyearLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) - Schedule of changes in share capital during the year [Line Items]" } } }, "localname": "EquityDetailsScheduleofchangesinsharecapitalduringtheyearLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "stringItemType" }, "ppbt_EquityDetailsScheduleofchangesinsharecapitalduringtheyearTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) - Schedule of changes in share capital during the year [Table]" } } }, "localname": "EquityDetailsScheduleofchangesinsharecapitalduringtheyearTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "stringItemType" }, "ppbt_EquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) [Table]" } } }, "localname": "EquityDetailsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ppbt_EquityMethodInvestmentsOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Direct ownership of equity.", "label": "EquityMethodInvestmentsOwnershipPercentage", "terseLabel": "Direct ownership of equity" } } }, "localname": "EquityMethodInvestmentsOwnershipPercentage", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "ppbt_ExchangeForAdditional": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ExchangeForAdditional", "terseLabel": "Exchange for additional (in Shares)" } } }, "localname": "ExchangeForAdditional", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "sharesItemType" }, "ppbt_ExerciseOfWarrantsEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "ExerciseOfWarrantsEquity", "terseLabel": "Warrants fair value" } } }, "localname": "ExerciseOfWarrantsEquity", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_ExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents exercise period.", "label": "ExercisePeriod", "terseLabel": "Exercisable period" } } }, "localname": "ExercisePeriod", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "durationItemType" }, "ppbt_ExpectedVolatilityPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.", "label": "ExpectedVolatilityPercentage", "terseLabel": "Expected volatility (%)" } } }, "localname": "ExpectedVolatilityPercentage", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "percentItemType" }, "ppbt_Expenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses.", "label": "Expenses", "terseLabel": "Expense amount" } } }, "localname": "Expenses", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_FairValueOfOptionsAndGrantsMeasured": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents fair value of these options and RSUs at the dates of grants was measured.", "label": "FairValueOfOptionsAndGrantsMeasured", "terseLabel": "Fair value of options and grants measured" } } }, "localname": "FairValueOfOptionsAndGrantsMeasured", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_FinanceExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance expenses.", "label": "FinanceExpenses", "terseLabel": "Finance expenses" } } }, "localname": "FinanceExpenses", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_FinanceExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FinanceExpensesAbstract", "terseLabel": "Finance expenses" } } }, "localname": "FinanceExpensesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofFinanceexpensesTable" ], "xbrltype": "stringItemType" }, "ppbt_FinanceExpensesIncomeNet": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]", "label": "FinanceExpensesIncomeNet", "terseLabel": "Finance expenses (income), net" } } }, "localname": "FinanceExpensesIncomeNet", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_FinanceExpensesNet": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expenses associated with financing activities of the entity.", "label": "FinanceExpensesNet", "totalLabel": "Finance expenses (income), net" } } }, "localname": "FinanceExpensesNet", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ppbt_FinancialAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FinancialAssetAbstract", "terseLabel": "Financial asset" } } }, "localname": "FinancialAssetAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffinancialinstrumentsmeasuredatfairvalueTable" ], "xbrltype": "stringItemType" }, "ppbt_FinancialInstrumentsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) [Line Items]" } } }, "localname": "FinancialInstrumentsDetailsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ppbt_FinancialInstrumentsDetailsScheduleoffairvaluemeasurementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) - Schedule of fair value measurement [Line Items]" } } }, "localname": "FinancialInstrumentsDetailsScheduleoffairvaluemeasurementLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable" ], "xbrltype": "stringItemType" }, "ppbt_FinancialInstrumentsDetailsScheduleoffairvaluemeasurementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) - Schedule of fair value measurement [Table]" } } }, "localname": "FinancialInstrumentsDetailsScheduleoffairvaluemeasurementTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable" ], "xbrltype": "stringItemType" }, "ppbt_FinancialInstrumentsDetailsScheduleoffinancialinstrumentsmeasuredatfairvalueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) - Schedule of financial instruments measured at fair value [Line Items]" } } }, "localname": "FinancialInstrumentsDetailsScheduleoffinancialinstrumentsmeasuredatfairvalueLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffinancialinstrumentsmeasuredatfairvalueTable" ], "xbrltype": "stringItemType" }, "ppbt_FinancialInstrumentsDetailsScheduleoffinancialinstrumentsmeasuredatfairvalueTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) - Schedule of financial instruments measured at fair value [Table]" } } }, "localname": "FinancialInstrumentsDetailsScheduleoffinancialinstrumentsmeasuredatfairvalueTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffinancialinstrumentsmeasuredatfairvalueTable" ], "xbrltype": "stringItemType" }, "ppbt_FinancialInstrumentsDetailsScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]" } } }, "localname": "FinancialInstrumentsDetailsScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "stringItemType" }, "ppbt_FinancialInstrumentsDetailsScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Table]" } } }, "localname": "FinancialInstrumentsDetailsScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "stringItemType" }, "ppbt_FinancialInstrumentsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments (Details) [Table]" } } }, "localname": "FinancialInstrumentsDetailsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ppbt_FundsRaisedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Funds raised amount.", "label": "FundsRaisedAmount", "terseLabel": "Company funds raised" } } }, "localname": "FundsRaisedAmount", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_GeneralAndAdministrativeExpensesOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.", "label": "GeneralAndAdministrativeExpensesOther", "terseLabel": "Other" } } }, "localname": "GeneralAndAdministrativeExpensesOther", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_GovernmentAuthorities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Government authorities.", "label": "GovernmentAuthorities", "terseLabel": "Government authorities" } } }, "localname": "GovernmentAuthorities", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "ppbt_GrossAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross amount.", "label": "GrossAmount", "terseLabel": "Gross amount" } } }, "localname": "GrossAmount", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_IPRDRelatedToFamewavesee5BBelowMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IPRDRelatedToFamewavesee5BBelowMember", "terseLabel": "IPR&D related to Famewave (see 5B below) [Member]" } } }, "localname": "IPRDRelatedToFamewavesee5BBelowMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "ppbt_IPRDRelatedToTyrNovosee5ABelowMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IPRDRelatedToTyrNovosee5ABelowMember", "terseLabel": "IPR&D related to TyrNovo (see 5A below) [Member]" } } }, "localname": "IPRDRelatedToTyrNovosee5ABelowMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "ppbt_ISASettlementseeAlsoNote13B": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "ISA settlement.", "label": "ISASettlementseeAlsoNote13B", "terseLabel": "ISA settlement (see also Note 13B)" } } }, "localname": "ISASettlementseeAlsoNote13B", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_IncomelossFromChangeInExchangeRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income loss from change in exchange rate.", "label": "IncomelossFromChangeInExchangeRate", "terseLabel": "Income (loss) from change in exchange rate" } } }, "localname": "IncomelossFromChangeInExchangeRate", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "monetaryItemType" }, "ppbt_IncomelossValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income loss value.", "label": "IncomelossValue", "terseLabel": "Income (loss) value" } } }, "localname": "IncomelossValue", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "monetaryItemType" }, "ppbt_IntangibleAssetsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Line Items]" } } }, "localname": "IntangibleAssetsDetailsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ppbt_IntangibleAssetsDetailsScheduleofintangibleassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of intangible assets [Line Items]" } } }, "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "ppbt_IntangibleAssetsDetailsScheduleofintangibleassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of intangible assets [Table]" } } }, "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "ppbt_IntangibleAssetsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Table]" } } }, "localname": "IntangibleAssetsDetailsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ppbt_IntangibleAssetsRecoverableAmountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets recoverable amount percentage.", "label": "IntangibleAssetsRecoverableAmountPercentage", "terseLabel": "Intangible assets recoverable amount percentage" } } }, "localname": "IntangibleAssetsRecoverableAmountPercentage", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "ppbt_InterestReceivedClassifiedAsFinancingActivities": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from interest received, classified as financing activities.", "label": "InterestReceivedClassifiedAsFinancingActivities", "terseLabel": "Interest received" } } }, "localname": "InterestReceivedClassifiedAsFinancingActivities", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_InvestmentWarrantExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price of the warrants.", "label": "InvestmentWarrantExercisePrice", "terseLabel": "Exercise price (in Dollars per share)" } } }, "localname": "InvestmentWarrantExercisePrice", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "ppbt_IsraelInnovationAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IsraelInnovationAuthorityMember", "terseLabel": "Israel Innovation Authority [Member]" } } }, "localname": "IsraelInnovationAuthorityMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ppbt_IssuanceOfAmericanDepositorySharesNetOfIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of American Depository Shares net of issuance costs.", "label": "IssuanceOfAmericanDepositorySharesNetOfIssuanceCosts", "terseLabel": "Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs" } } }, "localname": "IssuanceOfAmericanDepositorySharesNetOfIssuanceCosts", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ppbt_IssuedOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued of ordinary shares.", "label": "IssuedOfOrdinaryShares", "terseLabel": "Issued of ordinary shares" } } }, "localname": "IssuedOfOrdinaryShares", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "ppbt_IssuedOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued of shares.", "label": "IssuedOfShares", "terseLabel": "Issued of shares (in Shares)" } } }, "localname": "IssuedOfShares", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "sharesItemType" }, "ppbt_IssuedSecuritiesPublicOfferingDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of issued securities of public offering.", "label": "IssuedSecuritiesPublicOfferingDescription", "terseLabel": "Company issued securities, description" } } }, "localname": "IssuedSecuritiesPublicOfferingDescription", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ppbt_LeasesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) [Line Items]" } } }, "localname": "LeasesDetailsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "ppbt_LeasesDetailsScheduleofcarryingamountsofrighttouseassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of carrying amounts of right-to-use assets [Line Items]" } } }, "localname": "LeasesDetailsScheduleofcarryingamountsofrighttouseassetsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcarryingamountsofrighttouseassetsTable" ], "xbrltype": "stringItemType" }, "ppbt_LeasesDetailsScheduleofcarryingamountsofrighttouseassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of carrying amounts of right-to-use assets [Table]" } } }, "localname": "LeasesDetailsScheduleofcarryingamountsofrighttouseassetsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcarryingamountsofrighttouseassetsTable" ], "xbrltype": "stringItemType" }, "ppbt_LeasesDetailsScheduleofmaturityanalysisofthecompanysleaseliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of maturity analysis of the company's lease liabilities [Line Items]" } } }, "localname": "LeasesDetailsScheduleofmaturityanalysisofthecompanysleaseliabilitiesLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "stringItemType" }, "ppbt_LeasesDetailsScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) - Schedule of maturity analysis of the company's lease liabilities [Table]" } } }, "localname": "LeasesDetailsScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "stringItemType" }, "ppbt_LeasesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } }, "localname": "LeasesDetailsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "ppbt_LegalFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of legal fees.", "label": "LegalFee", "terseLabel": "Legal fees in connection with ISA investigation and class action lawsuits (see also Note 13B)" } } }, "localname": "LegalFee", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_LongtermDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of long-term deposits held by the entity.", "label": "LongtermDeposit", "terseLabel": "Long term deposits" } } }, "localname": "LongtermDeposit", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_LongtermLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-term lease liability.", "label": "LongtermLeaseLiability", "terseLabel": "Long-term lease liability" } } }, "localname": "LongtermLeaseLiability", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofmaturityanalysisofthecompanysleaseliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_LossContingencyActionTakenByCourtArbitratorOrMediator": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes important rulings or decisions made by the judge, arbitrator or mediator in the legal matter that could impact the outcome of the case.", "label": "LossContingencyActionTakenByCourtArbitratorOrMediator", "terseLabel": "Loss contingency actions taken by court arbitrator or mediator, description" } } }, "localname": "LossContingencyActionTakenByCourtArbitratorOrMediator", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ppbt_LossContingencyDamagePaidValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of damages paid to the plaintiff in the legal matter.", "label": "LossContingencyDamagePaidValue", "terseLabel": "Motion total amount" } } }, "localname": "LossContingencyDamagePaidValue", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_LossProfitForTheYearAttributableToTheOwnersOfTheCompanyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LossProfitForTheYearAttributableToTheOwnersOfTheCompanyAbstract", "terseLabel": "Loss (profit) for the year attributable to the owners of the Company:" } } }, "localname": "LossProfitForTheYearAttributableToTheOwnersOfTheCompanyAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "stringItemType" }, "ppbt_LossProfitPerShareDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LossProfitPerShareDiscontinuedOperationAbstract", "terseLabel": "Loss (profit) per share \u2013 Discontinued operation" } } }, "localname": "LossProfitPerShareDiscontinuedOperationAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "stringItemType" }, "ppbt_MaterialLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Material lease agreement.", "label": "MaterialLeaseAgreement", "terseLabel": "Material lease agreement" } } }, "localname": "MaterialLeaseAgreement", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "ppbt_MaterialLeaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MaterialLeaseAgreementsMember", "terseLabel": "Material Lease Agreements [Member]" } } }, "localname": "MaterialLeaseAgreementsMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "ppbt_MaximumRoyaltyPayableExcludingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum royalty amount that would be payable by TyrNovo, excluding interest.", "label": "MaximumRoyaltyPayableExcludingInterest", "terseLabel": "Maximum royalty payable excluding interest amount" } } }, "localname": "MaximumRoyaltyPayableExcludingInterest", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_NameOfInnovationAuthorityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NameOfInnovationAuthorityAxis", "terseLabel": "Name Of Innovation Authority [Axis]" } } }, "localname": "NameOfInnovationAuthorityAxis", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ppbt_NameOfInnovationAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NameOfInnovationAuthority [Domain]" } } }, "localname": "NameOfInnovationAuthorityDomain", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ppbt_NetAssetsAttributableToNoncontrollingInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of Mount of net assets attributable to non-controling interest.", "label": "NetAssetsAttributableToNoncontrollingInterest", "terseLabel": "Net assets attributable to non-controlling interests" } } }, "localname": "NetAssetsAttributableToNoncontrollingInterest", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofinformationrelatingtosubsidiarythathasmaterialnoncontrollinginterestsTable" ], "xbrltype": "monetaryItemType" }, "ppbt_NetAssetsAttributableToNoncontrollingInterests": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of net assets attributable to non-controlling interests.", "label": "NetAssetsAttributableToNoncontrollingInterests", "terseLabel": "Loss allocated to non-controlling interests" } } }, "localname": "NetAssetsAttributableToNoncontrollingInterests", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofinformationrelatingtosubsidiarythathasmaterialnoncontrollinginterestsTable" ], "xbrltype": "monetaryItemType" }, "ppbt_NewDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NewDirectorMember", "terseLabel": "New Director [Member]" } } }, "localname": "NewDirectorMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "ppbt_NisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NisMember", "terseLabel": "Nis [Member]" } } }, "localname": "NisMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ppbt_NonCashActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NonCashActivitiesAbstract", "terseLabel": "Non- Cash activities:" } } }, "localname": "NonCashActivitiesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "ppbt_NumberOfExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of warrants.", "label": "NumberOfExerciseOfWarrants", "terseLabel": "Exercise of warrants" } } }, "localname": "NumberOfExerciseOfWarrants", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable0" ], "xbrltype": "sharesItemType" }, "ppbt_NumberOfIssuanceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of issuance shares.", "label": "NumberOfIssuanceShares", "terseLabel": "Issuance of shares (See Note 5)" } } }, "localname": "NumberOfIssuanceShares", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable0" ], "xbrltype": "sharesItemType" }, "ppbt_NumberOfNonTradableWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Non Tradable Warrants.", "label": "NumberOfNonTradableWarrants", "terseLabel": "Number of non-tradable warrants (in Shares)" } } }, "localname": "NumberOfNonTradableWarrants", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "ppbt_NumberOfOperatingSegment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of operating segments.", "label": "NumberOfOperatingSegment", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegment", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/DiscontinuedOperationDetails" ], "xbrltype": "integerItemType" }, "ppbt_NumberOfOutstandingShareOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement.", "label": "NumberOfOutstandingShareOption", "periodEndLabel": "Outstanding on December 31", "periodStartLabel": "Outstanding on January 1" } } }, "localname": "NumberOfOutstandingShareOption", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable" ], "xbrltype": "sharesItemType" }, "ppbt_NumberOfShareOptionExercisableInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement.", "label": "NumberOfShareOptionExercisableInSharebasedPaymentArrangement", "terseLabel": "Exercisable on December 31" } } }, "localname": "NumberOfShareOptionExercisableInSharebasedPaymentArrangement", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable" ], "xbrltype": "sharesItemType" }, "ppbt_NumberOfShareOptionExpiredInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement.", "label": "NumberOfShareOptionExpiredInSharebasedPaymentArrangement", "terseLabel": "Expired and forfeited during the year" } } }, "localname": "NumberOfShareOptionExpiredInSharebasedPaymentArrangement", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable" ], "xbrltype": "sharesItemType" }, "ppbt_NumberOfShareOptionGrantedInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement.", "label": "NumberOfShareOptionGrantedInSharebasedPaymentArrangement", "terseLabel": "Granted during the year" } } }, "localname": "NumberOfShareOptionGrantedInSharebasedPaymentArrangement", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberandweightedaverageexercisepricesinUSDofshareoptionsTable" ], "xbrltype": "sharesItemType" }, "ppbt_NumberOfSharesUsedInCalculatingBasicDilutedLossprofitPerADSDiscontinuedOperation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumberOfSharesUsedInCalculatingBasicDilutedLossprofitPerADSDiscontinuedOperation", "terseLabel": "Number of ADSs used in calculating basic & diluted loss (profit) per ADS (in Shares)" } } }, "localname": "NumberOfSharesUsedInCalculatingBasicDilutedLossprofitPerADSDiscontinuedOperation", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "ppbt_NumberOfVestingOfRsus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Vesting Of Rsus.", "label": "NumberOfVestingOfRsus", "terseLabel": "Vesting of RSUs" } } }, "localname": "NumberOfVestingOfRsus", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable0" ], "xbrltype": "sharesItemType" }, "ppbt_OfficerAndEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OfficerAndEmployeeMember", "terseLabel": "Officer and Employee [Member]" } } }, "localname": "OfficerAndEmployeeMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "ppbt_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OfficersAndDirectorsMember", "terseLabel": "Officers And Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "ppbt_OptionOustanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option oustanding.", "label": "OptionOustanding", "terseLabel": "Option oustanding" } } }, "localname": "OptionOustanding", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_OptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OptionsMember", "terseLabel": "Options [Member]" } } }, "localname": "OptionsMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "ppbt_OrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OrdinaryShareMember", "terseLabel": "Ordinary Share [Member]" } } }, "localname": "OrdinaryShareMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "domainItemType" }, "ppbt_OtherCurenciesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OtherCurenciesMember", "terseLabel": "Balance in other currencies [Member]" } } }, "localname": "OtherCurenciesMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "domainItemType" }, "ppbt_OtherCurrentAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OtherCurrentAssetMember", "terseLabel": "Other current assets [Member]" } } }, "localname": "OtherCurrentAssetMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "domainItemType" }, "ppbt_OtherPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Payables.", "label": "OtherPayable", "terseLabel": "Other payables" } } }, "localname": "OtherPayable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_OtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OtherPayablesMember", "terseLabel": "Other payables [Member]" } } }, "localname": "OtherPayablesMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "domainItemType" }, "ppbt_OtherProfessionalFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other professional fees.", "label": "OtherProfessionalFees", "terseLabel": "Other professional fees" } } }, "localname": "OtherProfessionalFees", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_OutstandingOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding of ordinary shares.", "label": "OutstandingOfOrdinaryShares", "terseLabel": "Outstanding of ordinary shares" } } }, "localname": "OutstandingOfOrdinaryShares", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "ppbt_PPBT_ClassOfWarrantsOrRightTitleOfSecurityWarrantsOrRightsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item provides the title of issue of securities called for by warrants or rights outstanding.", "label": "PPBT_ClassOfWarrantsOrRightTitleOfSecurityWarrantsOrRightsOutstanding", "terseLabel": "Description of warrants rights" } } }, "localname": "PPBT_ClassOfWarrantsOrRightTitleOfSecurityWarrantsOrRightsOutstanding", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "ppbt_PayableToGovernmentAuthoritiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payable to government authorities.", "label": "PayableToGovernmentAuthoritiesCurrent", "terseLabel": "Government authorities" } } }, "localname": "PayableToGovernmentAuthoritiesCurrent", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_PaymentsToKeyManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PaymentsToKeyManagementMember", "terseLabel": "Payments To Key Management [Member]" } } }, "localname": "PaymentsToKeyManagementMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "domainItemType" }, "ppbt_PayrollRelatedPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value represents payable to related parties manage and update entries for the day.", "label": "PayrollRelatedPayables", "terseLabel": "Payroll related" } } }, "localname": "PayrollRelatedPayables", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_PercentageOfContractToAcquire": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract to acquire, percentage.", "label": "PercentageOfContractToAcquire", "terseLabel": "Contract to acquire, percentage" } } }, "localname": "PercentageOfContractToAcquire", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "xbrltype": "percentItemType" }, "ppbt_PossibleEffectsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PossibleEffectsMember", "terseLabel": "Possible effects [Member]" } } }, "localname": "PossibleEffectsMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable" ], "xbrltype": "domainItemType" }, "ppbt_PostEmploymentBenefitLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PostEmploymentBenefitLiabilitiesMember", "terseLabel": "Post-employment benefit liabilities [Member]" } } }, "localname": "PostEmploymentBenefitLiabilitiesMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "domainItemType" }, "ppbt_PreferredClassCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PreferredClassCMember", "terseLabel": "Class C Preferred Shares [Member]" } } }, "localname": "PreferredClassCMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "domainItemType" }, "ppbt_PreferredClassDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PreferredClassDMember", "terseLabel": "Class D Preferred Shares [Member]" } } }, "localname": "PreferredClassDMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "domainItemType" }, "ppbt_PreferredShareClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PreferredShareClassBMember", "terseLabel": "Class B Preferred Shares [Member]" } } }, "localname": "PreferredShareClassBMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "domainItemType" }, "ppbt_PreferredShareClassMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PreferredShareClassMember", "terseLabel": "Class A Preferred Shares [Member]" } } }, "localname": "PreferredShareClassMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofchangesinsharecapitalduringtheyearTable" ], "xbrltype": "domainItemType" }, "ppbt_PrepaidExpensesAndOtherReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other receivables.", "label": "PrepaidExpensesAndOtherReceivables", "terseLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpensesAndOtherReceivables", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "ppbt_PrincipalAssumptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PrincipalAssumptionsMember", "terseLabel": "Principal assumptions [Member]" } } }, "localname": "PrincipalAssumptionsMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable" ], "xbrltype": "domainItemType" }, "ppbt_PrivateAndPublicFinancingTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "PrivateAndPublicFinancingTotal", "terseLabel": "Private and public financing total value" } } }, "localname": "PrivateAndPublicFinancingTotal", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_ProceedsFromIssuingWarrants": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuing warrants.", "label": "ProceedsFromIssuingWarrants", "terseLabel": "Proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuingWarrants", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_ProfitLossAttributableToOwnersAndIncludingNonControllingInterests": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The profit (loss) attributable to owners of equity and including non-controlling interests.", "label": "ProfitLossAttributableToOwnersAndIncludingNonControllingInterests", "totalLabel": "Total Loss attributable" } } }, "localname": "ProfitLossAttributableToOwnersAndIncludingNonControllingInterests", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "ppbt_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PublicOfferingMember", "terseLabel": "Public offering [Member]", "verboseLabel": "Public Offering [Member]" } } }, "localname": "PublicOfferingMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "ppbt_PurchaseOfCommonStockAndWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company granted representative of the non traded warrants to purchase of common stock.", "label": "PurchaseOfCommonStockAndWarrants", "terseLabel": "Warrants to purchase shares (in Shares)" } } }, "localname": "PurchaseOfCommonStockAndWarrants", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "ppbt_RangesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RangesAxis", "terseLabel": "Ranges [Axis]" } } }, "localname": "RangesAxis", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ppbt_RangesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ranges [Domain]" } } }, "localname": "RangesDomain", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ppbt_ReceiptsFromWarrantExercise": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from receipts from warrant exercise.", "label": "ReceiptsFromWarrantExercise", "terseLabel": "Proceeds from exercise of warrant" } } }, "localname": "ReceiptsFromWarrantExercise", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_ReceiptsOnAccountsOfWarrant": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of receipts on account of warrants.", "label": "ReceiptsOnAccountsOfWarrant", "terseLabel": "Receipts on account of warrants" } } }, "localname": "ReceiptsOnAccountsOfWarrant", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ppbt_ReclassificationOfNontradableDerivativesUntilRegisteredForTrading": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of non-tradable derivatives until registered for trading.", "label": "ReclassificationOfNontradableDerivativesUntilRegisteredForTrading", "terseLabel": "Reclassification of non-tradable derivatives until registered for trading" } } }, "localname": "ReclassificationOfNontradableDerivativesUntilRegisteredForTrading", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_ReferenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ReferenceMember", "terseLabel": "Reference [Member]" } } }, "localname": "ReferenceMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofassumptionsofcarryingamountsofassetsandliabilitiesTable" ], "xbrltype": "domainItemType" }, "ppbt_ReimbursementOfLegalFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of reimbursement of legal fees.", "label": "ReimbursementOfLegalFees", "terseLabel": "Reimbursement of legal fees" } } }, "localname": "ReimbursementOfLegalFees", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_ResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.", "label": "ResearchAndDevelopmentExpenses", "terseLabel": "Research and development expense, total" } } }, "localname": "ResearchAndDevelopmentExpenses", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_ResultsOfDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ResultsOfDiscontinuedOperationAbstract", "terseLabel": "Results of discontinued operation" } } }, "localname": "ResultsOfDiscontinuedOperationAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofdiscontinuedoperationTable" ], "xbrltype": "stringItemType" }, "ppbt_RetainedEarning": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "RetainedEarning", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarning", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/GeneralDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_SalesAgreementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement shares.", "label": "SalesAgreementShares", "terseLabel": "Sales agreement (in Shares)" } } }, "localname": "SalesAgreementShares", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "ppbt_ScheduleOfAmountsRecognizedInProfitOrLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of amounts recognized in profit or loss [Abstract]" } } }, "localname": "ScheduleOfAmountsRecognizedInProfitOrLossAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assumptions of carrying amounts of assets and liabilities [Abstract]" } } }, "localname": "ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of assumptions of carrying amounts of assets and liabilities.", "label": "ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesTableTextBlock", "terseLabel": "Schedule of assumptions of carrying amounts of assets and liabilities" } } }, "localname": "ScheduleOfAssumptionsOfCarryingAmountsOfAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/BasisofPreparationoftheConsolidatedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of carrying amounts of right-to-use assets [Abstract]" } } }, "localname": "ScheduleOfCarryingAmountsOfRightToUseAssetsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of cash and cash equivalents [Abstract]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfChangesInExchangeRatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of changes in exchange rates [Abstract]" } } }, "localname": "ScheduleOfChangesInExchangeRatesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfChangesInShareCapitalDuringTheYearAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of changes in share capital during the year [Abstract]" } } }, "localname": "ScheduleOfChangesInShareCapitalDuringTheYearAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of defined contribution plan in respect of its employees [Abstract]" } } }, "localname": "ScheduleOfDefinedContributionPlanInRespectOfItsEmployeesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of discontinued operation [Abstract]" } } }, "localname": "ScheduleOfDiscontinuedOperationAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfDiscontinuedOperationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfDiscontinuedOperationTableTextBlock", "terseLabel": "Schedule of discontinued operation" } } }, "localname": "ScheduleOfDiscontinuedOperationTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/DiscontinuedOperationTables" ], "xbrltype": "textBlockItemType" }, "ppbt_ScheduleOfFairValueMeasurementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value measurement [Abstract]" } } }, "localname": "ScheduleOfFairValueMeasurementAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfFairValueMeasurementAtLevelsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PPBT_ScheduleOfFairValueMeasurementAtLevelsTableTextBlock.", "label": "ScheduleOfFairValueMeasurementAtLevelsTableTextBlock", "terseLabel": "Schedule of fair value measurement" } } }, "localname": "ScheduleOfFairValueMeasurementAtLevelsTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_ScheduleOfFinanceExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Finance expenses [Abstract]" } } }, "localname": "ScheduleOfFinanceExpensesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of financial instruments measured at fair value [Abstract]" } } }, "localname": "ScheduleOfFinancialInstrumentsMeasuredAtFairValueAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfFinancialInstrumentsMeasuredAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ScheduleOfFinancialInstrumentsMeasuredAtFairValueTableTextBlock.", "label": "ScheduleOfFinancialInstrumentsMeasuredAtFairValueTableTextBlock", "terseLabel": "Schedule of financial instruments measured at fair value" } } }, "localname": "ScheduleOfFinancialInstrumentsMeasuredAtFairValueTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ppbt_ScheduleOfInformationRelatingToSubsidiaryThatHasMaterialNonControllingInterestsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of information relating to subsidiary that has material non-controlling interests [Abstract]" } } }, "localname": "ScheduleOfInformationRelatingToSubsidiaryThatHasMaterialNonControllingInterestsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of intangible assets [Abstract]" } } }, "localname": "ScheduleOfIntangibleAssetsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of maturity analysis of the company's lease liabilities [Abstract]" } } }, "localname": "ScheduleOfMaturityAnalysisOfTheCompanysLeaseLiabilitiesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of other current assets [Abstract]" } } }, "localname": "ScheduleOfOtherCurrentAssetsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of other payables [Abstract]" } } }, "localname": "ScheduleOfOtherPayablesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfPostEmployeeBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of post-employee benefits [Abstract]" } } }, "localname": "ScheduleOfPostEmployeeBenefitsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of recognized amounts assets acquired and liabilities assumed [Abstract]" } } }, "localname": "ScheduleOfRecognizedAmountsAssetsAcquiredAndLiabilitiesAssumedAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfRecognizedInProfitOrLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to the effect of the overlay approach reclassification on profit or loss.", "label": "ScheduleOfRecognizedInProfitOrLossTableTextBlock", "terseLabel": "Schedule of amounts recognized in profit or loss" } } }, "localname": "ScheduleOfRecognizedInProfitOrLossTableTextBlock", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ppbt_ScheduleOfRecordedExpensesToExecutiveOfficersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of recorded expenses to executive officers [Abstract]" } } }, "localname": "ScheduleOfRecordedExpensesToExecutiveOfficersAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfResearchAndDevelopmentExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of research and development expenses [Abstract]" } } }, "localname": "ScheduleOfResearchAndDevelopmentExpensesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of sales, general and administrative expenses [Abstract]" } } }, "localname": "ScheduleOfSalesGeneralAndAdministrativeExpensesAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ScheduleOfSensitivityTestToPossibleChangesInUsdNisExchangeRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Abstract]" } } }, "localname": "ScheduleOfSensitivityTestToPossibleChangesInUsdNisExchangeRateAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_ServiceProviders": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of service providers.", "label": "ServiceProviders", "terseLabel": "Service providers" } } }, "localname": "ServiceProviders", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_ShareAndAdsIssuanceExpensesPaid": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for share and ADS issuance expenses paid, classified as financing activities.", "label": "ShareAndAdsIssuanceExpensesPaid", "negatedLabel": "ADS issuance expenses paid" } } }, "localname": "ShareAndAdsIssuanceExpensesPaid", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_ShareBasedCompensationResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expenses.", "label": "ShareBasedCompensationResearchAndDevelopmentExpense", "terseLabel": "Research and development expenses" } } }, "localname": "ShareBasedCompensationResearchAndDevelopmentExpense", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofsharebasedexpensesrecognizedTable" ], "xbrltype": "monetaryItemType" }, "ppbt_ShareBasedPaymentArrangementsOutstandingRestrictedStockUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangements outstanding restricted stock units.", "label": "ShareBasedPaymentArrangementsOutstandingRestrictedStockUnits", "periodEndLabel": "Outstanding at December 31", "periodStartLabel": "Outstanding at January 1" } } }, "localname": "ShareBasedPaymentArrangementsOutstandingRestrictedStockUnits", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberofRSUsTable" ], "xbrltype": "sharesItemType" }, "ppbt_ShareBasedPaymentArrangementsOutstandingRestrictedStockUnitsForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forfeited during the year.", "label": "ShareBasedPaymentArrangementsOutstandingRestrictedStockUnitsForfeited", "terseLabel": "Forfeited during the year" } } }, "localname": "ShareBasedPaymentArrangementsOutstandingRestrictedStockUnitsForfeited", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberofRSUsTable" ], "xbrltype": "sharesItemType" }, "ppbt_ShareBasedPaymentArrangementsRestrictedStockUnitsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based Payment Arrangements restricted stock units granted.", "label": "ShareBasedPaymentArrangementsRestrictedStockUnitsGranted", "terseLabel": "Granted during the year" } } }, "localname": "ShareBasedPaymentArrangementsRestrictedStockUnitsGranted", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberofRSUsTable" ], "xbrltype": "sharesItemType" }, "ppbt_ShareBasedPaymentArrangementsRestrictedStockUnitsVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based Payment Arrangements restricted stock units vested.", "label": "ShareBasedPaymentArrangementsRestrictedStockUnitsVested", "terseLabel": "Vested during the year" } } }, "localname": "ShareBasedPaymentArrangementsRestrictedStockUnitsVested", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofnumberofRSUsTable" ], "xbrltype": "sharesItemType" }, "ppbt_ShareCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share capital percentage.", "label": "ShareCapital", "terseLabel": "Share capital" } } }, "localname": "ShareCapital", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "ppbt_ShareCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareCapitalMember", "terseLabel": "Share Capital" } } }, "localname": "ShareCapitalMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "ppbt_SharebasedPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of share-based payments.", "label": "SharebasedPayment", "terseLabel": "Share-based payments (see also Note 11)" } } }, "localname": "SharebasedPayment", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "ppbt_SharebasedPaymentArrangementsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangements (Details) [Line Items]" } } }, "localname": "SharebasedPaymentArrangementsDetailsLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "stringItemType" }, "ppbt_SharebasedPaymentArrangementsDetailsSummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangements (Details) - Summary of options to service providers were measured at the fair value of the service [Line Items]" } } }, "localname": "SharebasedPaymentArrangementsDetailsSummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "stringItemType" }, "ppbt_SharebasedPaymentArrangementsDetailsSummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangements (Details) - Summary of options to service providers were measured at the fair value of the service [Table]" } } }, "localname": "SharebasedPaymentArrangementsDetailsSummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SummaryofoptionstoserviceprovidersweremeasuredatthefairvalueoftheserviceTable" ], "xbrltype": "stringItemType" }, "ppbt_SharebasedPaymentArrangementsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangements (Details) [Table]" } } }, "localname": "SharebasedPaymentArrangementsDetailsTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "stringItemType" }, "ppbt_SignificantUnobservableDividendYield": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividend yield", "label": "SignificantUnobservableDividendYield", "terseLabel": "dividend yield" } } }, "localname": "SignificantUnobservableDividendYield", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable" ], "xbrltype": "percentItemType" }, "ppbt_SignificantUnobservableInputsAnnualRiskFreeInteres": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual risk free interest", "label": "SignificantUnobservableInputsAnnualRiskFreeInteres", "terseLabel": "annual risk free interest" } } }, "localname": "SignificantUnobservableInputsAnnualRiskFreeInteres", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable" ], "xbrltype": "percentItemType" }, "ppbt_SignificantUnobservableInputsExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected term", "label": "SignificantUnobservableInputsExpectedTerm", "terseLabel": "expected term" } } }, "localname": "SignificantUnobservableInputsExpectedTerm", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable" ], "xbrltype": "durationItemType" }, "ppbt_SignificantUnobservableInputsExpectedVolatility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected volatility", "label": "SignificantUnobservableInputsExpectedVolatility", "terseLabel": "expected volatility" } } }, "localname": "SignificantUnobservableInputsExpectedVolatility", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleoffairvaluemeasurementTable" ], "xbrltype": "percentItemType" }, "ppbt_StockIssuedDuringPeriodSharesIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockIssuedDuringPeriodSharesIssues", "terseLabel": "Public offering issued by securities (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssues", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "ppbt_StockIssuedDuringPeriodValueIssues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "StockIssuedDuringPeriodValueIssues", "terseLabel": "Warrants to purchase value" } } }, "localname": "StockIssuedDuringPeriodValueIssues", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_StockIssuedDuringPeriodValueRestrictedStockUnitVesting": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock vesting issued during the period.", "label": "StockIssuedDuringPeriodValueRestrictedStockUnitVesting", "terseLabel": "Issuance of shares due to RSUs vesting" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockUnitVesting", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ppbt_StockOptionsGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock options granted.", "label": "StockOptionsGranted", "terseLabel": "Stock option granted" } } }, "localname": "StockOptionsGranted", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_SummaryOfNumberAndWeightedAverageExercisePricesInUsdOfShareOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of number and weighted average exercise prices (in USD) of share options [Abstract]" } } }, "localname": "SummaryOfNumberAndWeightedAverageExercisePricesInUsdOfShareOptionsAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_SummaryOfNumberOfRsusAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of number of RSUs [Abstract]" } } }, "localname": "SummaryOfNumberOfRsusAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_SummaryOfOptionsToServiceProvidersWereMeasuredAtTheFairValueOfTheServiceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of options to service providers were measured at the fair value of the service [Abstract]" } } }, "localname": "SummaryOfOptionsToServiceProvidersWereMeasuredAtTheFairValueOfTheServiceAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_SummaryOfShareBasedExpensesRecognizedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of share based expenses recognized [Abstract]" } } }, "localname": "SummaryOfShareBasedExpensesRecognizedAbstract", "nsuri": "http://Purplebiotech.com/20211231", "xbrltype": "stringItemType" }, "ppbt_THMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "THMMember", "terseLabel": "THM [Member]" } } }, "localname": "THMMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ppbt_TransactionsWithOwnersOfTheCompanyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TransactionsWithOwnersOfTheCompanyAbstract", "terseLabel": "Transactions with owners of the Company:" } } }, "localname": "TransactionsWithOwnersOfTheCompanyAbstract", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "ppbt_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofrecordedexpensestoexecutiveofficersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transactions and Balances with Related Parties (Details) - Schedule of recorded expenses to executive officers [Line Items]" } } }, "localname": "TransactionsandBalanceswithRelatedPartiesDetailsScheduleofrecordedexpensestoexecutiveofficersLineItems", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "stringItemType" }, "ppbt_TransactionsandBalanceswithRelatedPartiesDetailsScheduleofrecordedexpensestoexecutiveofficersTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transactions and Balances with Related Parties (Details) - Schedule of recorded expenses to executive officers [Table]" } } }, "localname": "TransactionsandBalanceswithRelatedPartiesDetailsScheduleofrecordedexpensestoexecutiveofficersTable", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "stringItemType" }, "ppbt_TransferOfDerivativeInstrumentFromLiabilityToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transfer of derivative instrument from liability to equity.", "label": "TransferOfDerivativeInstrumentFromLiabilityToEquity", "terseLabel": "Transfer of derivative instrument from liability to equity (see Note 10D)" } } }, "localname": "TransferOfDerivativeInstrumentFromLiabilityToEquity", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "ppbt_TypesOfCurrenciesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypesOfCurrenciesAxis", "terseLabel": "Types Of Currency [Axis]" } } }, "localname": "TypesOfCurrenciesAxis", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "stringItemType" }, "ppbt_TypesOfCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypesOfCurrencies [Domain]" } } }, "localname": "TypesOfCurrenciesDomain", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails", "http://Purplebiotech.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "domainItemType" }, "ppbt_TyrnovosTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TyrnovosTechnologyMember", "terseLabel": "Tyrnovos Technology [Member]" } } }, "localname": "TyrnovosTechnologyMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ppbt_UpRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UpRangeOneMember", "terseLabel": "Up Range One [Member]" } } }, "localname": "UpRangeOneMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsensitivitytesttopossiblechangesinUSDNISexchangerateTable" ], "xbrltype": "domainItemType" }, "ppbt_UsdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UsdMember", "terseLabel": "Balance in USD [Member]" } } }, "localname": "UsdMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "domainItemType" }, "ppbt_VestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents vesting period.", "label": "VestingPeriod", "terseLabel": "Vesting period" } } }, "localname": "VestingPeriod", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "durationItemType" }, "ppbt_WarrantExercisePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "WarrantExercisePrice", "terseLabel": "Warrant exercise price" } } }, "localname": "WarrantExercisePrice", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_WarrantsInvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrants invested.", "label": "WarrantsInvested", "terseLabel": "Warrants invested (in Dollars)" } } }, "localname": "WarrantsInvested", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ppbt_WarrantsIssuanceExpensesPaid": { "auth_ref": [], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for warrants issuance expenses paid, classified as financing activities.", "label": "WarrantsIssuanceExpensesPaid", "negatedLabel": "Warrants issuance expenses paid" } } }, "localname": "WarrantsIssuanceExpensesPaid", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "ppbt_WarrantsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of warrants, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "WarrantsTerm", "terseLabel": "Warrants term" } } }, "localname": "WarrantsTerm", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "durationItemType" }, "ppbt_WeighedAverageExercisePriceOfShareOptionsVestingInPeriodSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of share options vested.", "label": "WeighedAverageExercisePriceOfShareOptionsVestingInPeriodSharebasedPaymentArrangement", "terseLabel": "Options exercise price (in Dollars per share)" } } }, "localname": "WeighedAverageExercisePriceOfShareOptionsVestingInPeriodSharebasedPaymentArrangement", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "perShareItemType" }, "ppbt_YissumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "YissumMember", "terseLabel": "Yissum [Member]" } } }, "localname": "YissumMember", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/CommitmentsandContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ppbt_noncontrollingInterests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-controlling interests.", "label": "noncontrollingInterests", "terseLabel": "Non-controlling interests" } } }, "localname": "noncontrollingInterests", "nsuri": "http://Purplebiotech.com/20211231", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "percentItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable", "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/ScheduleofrecordedexpensestoexecutiveofficersTable" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r232", "r234", "r238", "r239", "r258", "r259", "r260", "r261", "r262", "r263", "r282", "r298", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r232", "r234", "r238", "r239", "r258", "r259", "r260", "r261", "r262", "r263", "r282", "r298", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "label": "Officer [Member]", "terseLabel": "Officer [Member]" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r232", "r234", "r236", "r238", "r239", "r258", "r259", "r260", "r261", "r262", "r263", "r282", "r298", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r232", "r234", "r236", "r238", "r239", "r258", "r259", "r260", "r261", "r262", "r263", "r282", "r298", "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r201", "r202", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r233", "r235", "r246", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r310", "r311", "r312", "r313", "r314", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r217", "r218", "r220", "r221", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r217", "r219" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/SummaryofsharebasedexpensesrecognizedTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r184", "r185", "r186", "r187", "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r207", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r241", "r242", "r243", "r244", "r245", "r247", "r248", "r297" ], "calculation": { "http://Purplebiotech.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Loss for the year from continuing operation" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r237", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r237", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r237", "r249", "r251", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development Expenses [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.", "label": "Schedule of Realized Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfRealizedGainLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of recognized amounts assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Sales, General and Administrative Expenses total" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based payments (see also Note 11)" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/ScheduleofsalesgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r201", "r202", "r204", "r205", "r206", "r233", "r235", "r246", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r310", "r311", "r312", "r313", "r314", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/SharebasedPaymentArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Receipts on account of warrants", "verboseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://Purplebiotech.com/role/EquityDetails", "http://Purplebiotech.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "IG63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r102": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "10", "Paragraph": "22", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22&doctype=Standard", "URIDate": "2021-03-24" }, "r103": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2021-03-24" }, "r104": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r106": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r107": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r108": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r109": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r111": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r112": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r113": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r118": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r119": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r121": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r122": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r123": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2021-03-24" }, "r124": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2021-03-24" }, "r125": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2021-03-24" }, "r126": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2021-03-24" }, "r131": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24" }, "r133": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r134": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r135": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r136": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r137": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "o", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2021-03-24" }, "r144": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "IE72", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_IE72&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r147": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r148": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r149": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_c&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "q", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_d&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Section": "Example 11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&doctype=Implementation%20Guidance&dita_xref=IFRS05_ex11_TI", "URIDate": "2021-03-24" }, "r152": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Section": "Presentation and disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI", "URIDate": "2021-03-24" }, "r153": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r154": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "24G", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24G_c&doctype=Standard", "URIDate": "2021-03-24" }, "r155": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r156": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r157": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r158": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r159": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "r", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2021-03-24" }, "r161": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard", "URIDate": "2021-03-24" }, "r162": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24" }, "r163": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r164": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r166": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r167": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r168": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2021-03-24" }, "r169": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r171": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r172": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r173": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r174": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r175": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r177": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r178": { "IssueDate": "2021-01-01", "Name": "IAS", "Note": "Effective 2023-01-01", "Number": "1", "Paragraph": "82", "Subparagraph": "ac", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_ac&doctype=Standard", "URIDate": "2021-03-24" }, "r179": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "56", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_56&doctype=Standard", "URIDate": "2021-03-24" }, "r180": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24" }, "r181": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r182": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24" }, "r183": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "86", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard", "URIDate": "2021-03-24" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2021-03-24" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard", "URIDate": "2021-03-24" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2021-03-24" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r28": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r29": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r302": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r303": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r304": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r305": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r306": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r307": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r308": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r309": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r310": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r311": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r312": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r313": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r314": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r315": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r316": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r317": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r318": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "ea", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_ea&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_e&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_f&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2021-03-24" }, "r51": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_h_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "57", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_57_c&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18A&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "4", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_4&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "68", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "86", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS37_g84-92_TI", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "14", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44_b&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r95": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r99": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" } }, "version": "2.1" }